source,target,relation,sentence,doi,distance_score
trametinib,sorafenib,identify,"We identified four host-directed drugs, donepezil, dH-ergocristine, trametinib and sorafenib, that could potentially be repurposed to treat coronavirus infections.",10.1101/2025.10.15.682635,0.3333333333333333
trametinib,coronavirus infections,identify,"We identified four host-directed drugs, donepezil, dH-ergocristine, trametinib and sorafenib, that could potentially be repurposed to treat coronavirus infections.",10.1101/2025.10.15.682635,0.08333333333333333
sorafenib,coronavirus infections,identify,"We identified four host-directed drugs, donepezil, dH-ergocristine, trametinib and sorafenib, that could potentially be repurposed to treat coronavirus infections.",10.1101/2025.10.15.682635,0.1
Tyrosine,pan-coronaviruses infection,perform,"Here, we performed a genome-wide CRISPRi screening to identify the host protein, Hepatocyte Growth Factor-Regulated Tyrosine Kinase Substrate (HGS), as essential for the pan-coronaviruses infection both in vitro and in vivo.",10.1101/2025.10.17.683077,0.08333333333333333
riboflavin tetrabutyrate,RTB,identify,"Leveraging this interaction, we designed M-derived peptides and screened over 5,000 FDA-approved drugs, identifying riboflavin tetrabutyrate (RTB).",10.1101/2025.10.17.683077,0.25
riboflavin tetrabutyrate,RTB,identify,"Leveraging this interaction, we designed M-derived peptides and screened over 5,000 FDA-approved drugs, identifying riboflavin tetrabutyrate (RTB).",10.1101/2025.10.17.683077,0.25
riboflavin tetrabutyrate,RTB,identify,"Leveraging this interaction, we designed M-derived peptides and screened over 5,000 FDA-approved drugs, identifying riboflavin tetrabutyrate (RTB).",10.1101/2025.10.17.683077,0.25
RTB,RTB,identify,"Leveraging this interaction, we designed M-derived peptides and screened over 5,000 FDA-approved drugs, identifying riboflavin tetrabutyrate (RTB).",10.1101/2025.10.17.683077,1.0
RTB,RTB,identify,"Leveraging this interaction, we designed M-derived peptides and screened over 5,000 FDA-approved drugs, identifying riboflavin tetrabutyrate (RTB).",10.1101/2025.10.17.683077,1.0
RTB,RTB,identify,"Leveraging this interaction, we designed M-derived peptides and screened over 5,000 FDA-approved drugs, identifying riboflavin tetrabutyrate (RTB).",10.1101/2025.10.17.683077,1.0
RTB,RTB,bind,"Both the peptides and RTB bind HGS and disrupt its interaction with the M protein, leading to M retention in the ER and subsequent blockade of virion assembly.",10.1101/2025.10.17.683077,1.0
RTB,RTB,bind,"Both the peptides and RTB bind HGS and disrupt its interaction with the M protein, leading to M retention in the ER and subsequent blockade of virion assembly.",10.1101/2025.10.17.683077,1.0
RTB,RTB,bind,"Both the peptides and RTB bind HGS and disrupt its interaction with the M protein, leading to M retention in the ER and subsequent blockade of virion assembly.",10.1101/2025.10.17.683077,1.0
RTB,RTB,identify,"Collectively, our findings establish HGS as a druggable host target and identify RTB as a promising broad-spectrum antiviral candidate.",10.1101/2025.10.17.683077,1.0
RTB,RTB,identify,"Collectively, our findings establish HGS as a druggable host target and identify RTB as a promising broad-spectrum antiviral candidate.",10.1101/2025.10.17.683077,1.0
RTB,RTB,identify,"Collectively, our findings establish HGS as a druggable host target and identify RTB as a promising broad-spectrum antiviral candidate.",10.1101/2025.10.17.683077,1.0
nilotinib,tecovirimat,show,One top-ranked drug nilotinib is experimentally shown to have a significant 69% of antiviral efficacy of the FDA-approved antiviral tecovirimat (TPOXX(R) or ST-246).,10.1101/2025.10.12.681938,0.05555555555555555
nilotinib,ST-246,show,One top-ranked drug nilotinib is experimentally shown to have a significant 69% of antiviral efficacy of the FDA-approved antiviral tecovirimat (TPOXX(R) or ST-246).,10.1101/2025.10.12.681938,0.043478260869565216
tecovirimat,ST-246,show,One top-ranked drug nilotinib is experimentally shown to have a significant 69% of antiviral efficacy of the FDA-approved antiviral tecovirimat (TPOXX(R) or ST-246).,10.1101/2025.10.12.681938,0.16666666666666666
SARS-CoV-2 infection,SARS-CoV-2 infection,demonstrate,"We recently described AVI-4206 (1), a potent and selective inhibitor of the SARS-CoV-2 ADP-ribosylhydrolase Mac1 based on a 9H-pyrimido[4,5-b]indole core, the first Mac1 inhibitor to demonstrate antiviral efficacy in mouse models of SARS-CoV-2 infection, but requiring IP administration and frequent dosing.",10.1101/2025.10.11.681833,1.0
urea,hydrogen bond donor,replace,"Multiple strategies were pursued to overcome these issues, including replacing a urea function to reduce hydrogen bond donor count.",10.1101/2025.10.11.681833,0.2
urea,urea,replace,"Multiple strategies were pursued to overcome these issues, including replacing a urea function to reduce hydrogen bond donor count.",10.1101/2025.10.11.681833,1.0
urea,hydrogen bond donor,replace,"Multiple strategies were pursued to overcome these issues, including replacing a urea function to reduce hydrogen bond donor count.",10.1101/2025.10.11.681833,0.2
urea,urea,deliver,"While heterocyclic urea mimetics could deliver analogs like AVI-6318 (3) with potencies and ADME profiles similar to 1, abrogation of the P-gp liability was finally achieved with entirely non-polar substituents in place of urea.",10.1101/2025.10.11.681833,1.0
once-daily,SARS-CoV-2 infection,lead,"Thus, AVI-6451 (4) is a potent Mac1 inhibitor lead with low intrinsic clearance, high oral bioavailability, and antiviral efficacy with once-daily oral administration in a mouse model of SARS-CoV-2 infection.",10.1101/2025.10.11.681833,0.1111111111111111
SARS-CoV-2 infection,SARS-CoV-2 infection,lead,"Thus, AVI-6451 (4) is a potent Mac1 inhibitor lead with low intrinsic clearance, high oral bioavailability, and antiviral efficacy with once-daily oral administration in a mouse model of SARS-CoV-2 infection.",10.1101/2025.10.11.681833,1.0
once-daily,SARS-CoV-2 infection,lead,"Thus, AVI-6451 (4) is a potent Mac1 inhibitor lead with low intrinsic clearance, high oral bioavailability, and antiviral efficacy with once-daily oral administration in a mouse model of SARS-CoV-2 infection.",10.1101/2025.10.11.681833,0.1111111111111111
uridine,ARCA,contain,We examined different combinations of linear vectors: containing either N1-methylpseudouridines or uridine and capped with either ARCA (m7G(5')ppp(5')G) or CleanCap (m7G(5')ppp(5')m2G).,10.1101/2025.10.13.682008,0.16666666666666666
PASC,infection,develop,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101,0.14285714285714285
PASC,PASC,develop,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101,1.0
PASC,infection,develop,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101,0.14285714285714285
PASC,PASC,develop,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101,1.0
PASC,infection,develop,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101,0.14285714285714285
PASC,PASC,develop,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101,1.0
PASC,PASC,develop,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101,1.0
PASC,infection,develop,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101,0.14285714285714285
infection,infection,develop,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101,1.0
PASC,infection,develop,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101,0.14285714285714285
infection,infection,develop,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101,1.0
PASC,infection,develop,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101,0.14285714285714285
PASC,infection,develop,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101,0.14285714285714285
PASC,infection,develop,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101,0.14285714285714285
PASC,PASC,develop,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101,1.0
PASC,infection,develop,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101,0.14285714285714285
PASC,PASC,develop,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101,1.0
PASC,PASC,develop,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101,1.0
PASC,infection,develop,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101,0.14285714285714285
infection,infection,develop,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101,1.0
PASC,infection,develop,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101,0.14285714285714285
PASC,infection,develop,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101,0.14285714285714285
PASC,infection,develop,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101,0.14285714285714285
PASC,PASC,develop,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101,1.0
PASC,PASC,develop,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101,1.0
PASC,infection,develop,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101,0.14285714285714285
PASC,infection,develop,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101,0.14285714285714285
PASC,PASC,develop,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101,1.0
PASC,infection,infect,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101,0.045454545454545456
PASC,PASC,identify,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101,1.0
PASC,infected with SARS-CoV-2 and viral,identify,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101,0.2
PASC,infection,infect,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101,0.045454545454545456
PASC,PASC,identify,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101,1.0
PASC,infection,infect,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101,0.045454545454545456
PASC,PASC,identify,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101,1.0
PASC,PASC,identify,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101,1.0
PASC,infection,infect,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101,0.045454545454545456
infected with SARS-CoV-2 and viral,infection,identify,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101,0.05555555555555555
infection,infection,evaluate,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101,1.0
PASC,infection,infect,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101,0.045454545454545456
infection,infection,evaluate,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101,1.0
PASC,infection,infect,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101,0.045454545454545456
PASC,infection,infect,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101,0.045454545454545456
PASC,infected with SARS-CoV-2 and viral,identify,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101,0.2
PASC,infection,infect,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101,0.045454545454545456
PASC,PASC,identify,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101,1.0
PASC,infection,infect,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101,0.045454545454545456
PASC,PASC,identify,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101,1.0
PASC,PASC,identify,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101,1.0
infected with SARS-CoV-2 and viral,infection,identify,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101,0.05555555555555555
PASC,infected with SARS-CoV-2 and viral,identify,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101,0.2
infected with SARS-CoV-2 and viral,infection,identify,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101,0.05555555555555555
PASC,infected with SARS-CoV-2 and viral,identify,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101,0.2
PASC,infected with SARS-CoV-2 and viral,identify,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101,0.2
PASC,infection,infect,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101,0.045454545454545456
infection,infection,evaluate,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101,1.0
PASC,infection,infect,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101,0.045454545454545456
PASC,infection,infect,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101,0.045454545454545456
PASC,infection,infect,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101,0.045454545454545456
PASC,PASC,identify,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101,1.0
PASC,PASC,identify,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101,1.0
PASC,infection,infect,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101,0.045454545454545456
PASC,infection,infect,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101,0.045454545454545456
PASC,PASC,identify,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101,1.0
PASC,PASC,observe,Sex differences were not observed in virus replication or persistence of viral RNA in pulmonary or extrapulmonary tissues in acute or PASC phases.,10.1101/2025.10.13.682101,1.0
PASC,PASC,observe,Sex differences were not observed in virus replication or persistence of viral RNA in pulmonary or extrapulmonary tissues in acute or PASC phases.,10.1101/2025.10.13.682101,1.0
PASC,PASC,observe,Sex differences were not observed in virus replication or persistence of viral RNA in pulmonary or extrapulmonary tissues in acute or PASC phases.,10.1101/2025.10.13.682101,1.0
PASC,PASC,observe,Sex differences were not observed in virus replication or persistence of viral RNA in pulmonary or extrapulmonary tissues in acute or PASC phases.,10.1101/2025.10.13.682101,1.0
PASC,PASC,observe,Sex differences were not observed in virus replication or persistence of viral RNA in pulmonary or extrapulmonary tissues in acute or PASC phases.,10.1101/2025.10.13.682101,1.0
PASC,PASC,observe,Sex differences were not observed in virus replication or persistence of viral RNA in pulmonary or extrapulmonary tissues in acute or PASC phases.,10.1101/2025.10.13.682101,1.0
PASC,PASC,observe,Sex differences were not observed in virus replication or persistence of viral RNA in pulmonary or extrapulmonary tissues in acute or PASC phases.,10.1101/2025.10.13.682101,1.0
PASC,PASC,observe,Sex differences were not observed in virus replication or persistence of viral RNA in pulmonary or extrapulmonary tissues in acute or PASC phases.,10.1101/2025.10.13.682101,1.0
PASC,PASC,observe,Sex differences were not observed in virus replication or persistence of viral RNA in pulmonary or extrapulmonary tissues in acute or PASC phases.,10.1101/2025.10.13.682101,1.0
PASC,PASC,observe,Sex differences were not observed in virus replication or persistence of viral RNA in pulmonary or extrapulmonary tissues in acute or PASC phases.,10.1101/2025.10.13.682101,1.0
infection,infection,exhibit,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101,1.0
infection,infection,exhibit,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101,1.0
infection,neurocognitive and behavioral impairments,exhibit,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101,0.14285714285714285
infection,neuroinflammation,exhibit,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101,0.047619047619047616
infection,neuroinflammation,exhibit,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101,0.047619047619047616
infection,infection,exhibit,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101,1.0
infection,neurocognitive and behavioral impairments,exhibit,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101,0.14285714285714285
infection,neuroinflammation,exhibit,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101,0.047619047619047616
infection,neuroinflammation,exhibit,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101,0.047619047619047616
infection,neurocognitive and behavioral impairments,exhibit,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101,0.14285714285714285
infection,neuroinflammation,exhibit,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101,0.047619047619047616
infection,neuroinflammation,exhibit,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101,0.047619047619047616
neurocognitive and behavioral impairments,neuroinflammation,exhibit,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101,0.06666666666666667
neurocognitive and behavioral impairments,neuroinflammation,exhibit,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101,0.06666666666666667
neuroinflammation,neuroinflammation,exhibit,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101,1.0
PASC,PASC,mediate,Sex differences in inflammation and cognitive phenotypes during PASC were mediated by the presence of two X chromosomes.,10.1101/2025.10.13.682101,1.0
PASC,PASC,mediate,Sex differences in inflammation and cognitive phenotypes during PASC were mediated by the presence of two X chromosomes.,10.1101/2025.10.13.682101,1.0
inflammation,PASC,mediate,Sex differences in inflammation and cognitive phenotypes during PASC were mediated by the presence of two X chromosomes.,10.1101/2025.10.13.682101,0.16666666666666666
PASC,PASC,mediate,Sex differences in inflammation and cognitive phenotypes during PASC were mediated by the presence of two X chromosomes.,10.1101/2025.10.13.682101,1.0
PASC,PASC,mediate,Sex differences in inflammation and cognitive phenotypes during PASC were mediated by the presence of two X chromosomes.,10.1101/2025.10.13.682101,1.0
inflammation,PASC,mediate,Sex differences in inflammation and cognitive phenotypes during PASC were mediated by the presence of two X chromosomes.,10.1101/2025.10.13.682101,0.16666666666666666
PASC,PASC,mediate,Sex differences in inflammation and cognitive phenotypes during PASC were mediated by the presence of two X chromosomes.,10.1101/2025.10.13.682101,1.0
inflammation,PASC,mediate,Sex differences in inflammation and cognitive phenotypes during PASC were mediated by the presence of two X chromosomes.,10.1101/2025.10.13.682101,0.16666666666666666
PASC,PASC,mediate,Sex differences in inflammation and cognitive phenotypes during PASC were mediated by the presence of two X chromosomes.,10.1101/2025.10.13.682101,1.0
PASC,PASC,mediate,Sex differences in inflammation and cognitive phenotypes during PASC were mediated by the presence of two X chromosomes.,10.1101/2025.10.13.682101,1.0
inflammation,PASC,mediate,Sex differences in inflammation and cognitive phenotypes during PASC were mediated by the presence of two X chromosomes.,10.1101/2025.10.13.682101,0.16666666666666666
inflammation,PASC,mediate,Sex differences in inflammation and cognitive phenotypes during PASC were mediated by the presence of two X chromosomes.,10.1101/2025.10.13.682101,0.16666666666666666
PASC,PASC,mediate,Sex differences in inflammation and cognitive phenotypes during PASC were mediated by the presence of two X chromosomes.,10.1101/2025.10.13.682101,1.0
PASC,PASC,mediate,Sex differences in inflammation and cognitive phenotypes during PASC were mediated by the presence of two X chromosomes.,10.1101/2025.10.13.682101,1.0
inflammation,PASC,mediate,Sex differences in inflammation and cognitive phenotypes during PASC were mediated by the presence of two X chromosomes.,10.1101/2025.10.13.682101,0.16666666666666666
inflammation,PASC,mediate,Sex differences in inflammation and cognitive phenotypes during PASC were mediated by the presence of two X chromosomes.,10.1101/2025.10.13.682101,0.16666666666666666
inflammation,PASC,mediate,Sex differences in inflammation and cognitive phenotypes during PASC were mediated by the presence of two X chromosomes.,10.1101/2025.10.13.682101,0.16666666666666666
inflammation,inflammation,mediate,Sex differences in inflammation and cognitive phenotypes during PASC were mediated by the presence of two X chromosomes.,10.1101/2025.10.13.682101,1.0
PASC,PASC,mediate,Sex differences in inflammation and cognitive phenotypes during PASC were mediated by the presence of two X chromosomes.,10.1101/2025.10.13.682101,1.0
inflammation,PASC,mediate,Sex differences in inflammation and cognitive phenotypes during PASC were mediated by the presence of two X chromosomes.,10.1101/2025.10.13.682101,0.16666666666666666
inflammation,PASC,mediate,Sex differences in inflammation and cognitive phenotypes during PASC were mediated by the presence of two X chromosomes.,10.1101/2025.10.13.682101,0.16666666666666666
PASC,PASC,present,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,1.0
PASC,PASC,present,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,1.0
neuroinflammation,PASC,present,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,0.3333333333333333
PASC,inflammation,present,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,0.06666666666666667
PASC,PASC,present,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,1.0
neuroinflammation,PASC,present,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,0.3333333333333333
PASC,PASC,present,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,1.0
PASC,inflammation,present,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,0.06666666666666667
PASC,chronic disease,present,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,0.058823529411764705
PASC,PASC,present,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,1.0
neuroinflammation,PASC,present,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,0.3333333333333333
PASC,inflammation,present,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,0.06666666666666667
PASC,PASC,present,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,1.0
neuroinflammation,PASC,present,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,0.3333333333333333
PASC,PASC,present,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,1.0
PASC,inflammation,present,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,0.06666666666666667
PASC,chronic disease,present,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,0.058823529411764705
neuroinflammation,PASC,present,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,0.3333333333333333
PASC,inflammation,present,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,0.06666666666666667
PASC,PASC,present,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,1.0
neuroinflammation,PASC,present,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,0.3333333333333333
PASC,PASC,present,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,1.0
PASC,inflammation,present,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,0.06666666666666667
PASC,chronic disease,present,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,0.058823529411764705
neuroinflammation,inflammation,present,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,0.058823529411764705
neuroinflammation,PASC,present,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,0.3333333333333333
neuroinflammation,neuroinflammation,present,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,1.0
neuroinflammation,PASC,present,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,0.3333333333333333
neuroinflammation,inflammation,present,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,0.058823529411764705
neuroinflammation,chronic disease,present,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,0.05263157894736842
PASC,inflammation,present,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,0.06666666666666667
neuroinflammation,inflammation,present,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,0.058823529411764705
PASC,inflammation,present,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,0.06666666666666667
inflammation,inflammation,regulate,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,1.0
inflammation,chronic disease,regulate,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,0.3333333333333333
neuroinflammation,PASC,present,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,0.3333333333333333
PASC,PASC,present,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,1.0
PASC,inflammation,present,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,0.06666666666666667
PASC,chronic disease,present,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,0.058823529411764705
neuroinflammation,PASC,present,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,0.3333333333333333
neuroinflammation,inflammation,present,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,0.058823529411764705
neuroinflammation,chronic disease,present,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,0.05263157894736842
PASC,inflammation,present,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,0.06666666666666667
PASC,chronic disease,present,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,0.058823529411764705
inflammation,chronic disease,regulate,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101,0.3333333333333333
infection,infection,unknown,The relationship between the extracellular matrix and the host immune response to infection is severely understudied.,10.1101/2025.10.13.682000,1.0
anti-CD44,infection,confer,"Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection.",10.1101/2025.10.13.682000,0.043478260869565216
weight loss,infection,reduce,"Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection.",10.1101/2025.10.13.682000,0.07692307692307693
infection,infection,reduce,"Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection.",10.1101/2025.10.13.682000,1.0
anti-CD44,infection,confer,"Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection.",10.1101/2025.10.13.682000,0.043478260869565216
anti-CD44,infection,confer,"Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection.",10.1101/2025.10.13.682000,0.043478260869565216
anti-CD44,infection,confer,"Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection.",10.1101/2025.10.13.682000,0.043478260869565216
anti-CD44,weight loss,confer,"Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection.",10.1101/2025.10.13.682000,0.09090909090909091
anti-CD44,infection,confer,"Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection.",10.1101/2025.10.13.682000,0.043478260869565216
anti-CD44,anti-CD44,confer,"Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection.",10.1101/2025.10.13.682000,1.0
anti-CD44,anti-CD44,confer,"Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection.",10.1101/2025.10.13.682000,1.0
anti-CD44,anti-CD44,confer,"Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection.",10.1101/2025.10.13.682000,1.0
weight loss,infection,reduce,"Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection.",10.1101/2025.10.13.682000,0.07692307692307693
anti-CD44,weight loss,confer,"Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection.",10.1101/2025.10.13.682000,0.09090909090909091
anti-CD44,weight loss,confer,"Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection.",10.1101/2025.10.13.682000,0.09090909090909091
anti-CD44,weight loss,confer,"Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection.",10.1101/2025.10.13.682000,0.09090909090909091
anti-CD44,infection,confer,"Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection.",10.1101/2025.10.13.682000,0.043478260869565216
anti-CD44,infection,confer,"Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection.",10.1101/2025.10.13.682000,0.043478260869565216
anti-CD44,infection,confer,"Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection.",10.1101/2025.10.13.682000,0.043478260869565216
anti-CD44,anti-CD44,confer,"Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection.",10.1101/2025.10.13.682000,1.0
anti-CD44,anti-CD44,confer,"Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection.",10.1101/2025.10.13.682000,1.0
anti-CD44,anti-CD44,confer,"Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection.",10.1101/2025.10.13.682000,1.0
anti-CD44,anti-CD44,decrease,We show that anti-CD44 treatment decreases many key cytokines and chemokines in the bronchoalveolar lavage fluid on Day 4.,10.1101/2025.10.13.682000,1.0
anti-CD44,anti-CD44,decrease,We show that anti-CD44 treatment decreases many key cytokines and chemokines in the bronchoalveolar lavage fluid on Day 4.,10.1101/2025.10.13.682000,1.0
anti-CD44,anti-CD44,decrease,We show that anti-CD44 treatment decreases many key cytokines and chemokines in the bronchoalveolar lavage fluid on Day 4.,10.1101/2025.10.13.682000,1.0
anti-CD44,anti-CD44,decrease,We show that anti-CD44 treatment decreases many key cytokines and chemokines in the bronchoalveolar lavage fluid on Day 4.,10.1101/2025.10.13.682000,1.0
anti-CD44,anti-CD44,decrease,We show that anti-CD44 treatment decreases many key cytokines and chemokines in the bronchoalveolar lavage fluid on Day 4.,10.1101/2025.10.13.682000,1.0
anti-CD44,anti-CD44,decrease,We show that anti-CD44 treatment decreases many key cytokines and chemokines in the bronchoalveolar lavage fluid on Day 4.,10.1101/2025.10.13.682000,1.0
anti-CD44,anti-CD44,reduce,"With flow cytometry, we show that anti-CD44 reduces the numbers of neutrophils in infected lungs.",10.1101/2025.10.13.682000,1.0
anti-CD44,anti-CD44,reduce,"With flow cytometry, we show that anti-CD44 reduces the numbers of neutrophils in infected lungs.",10.1101/2025.10.13.682000,1.0
anti-CD44,anti-CD44,reduce,"With flow cytometry, we show that anti-CD44 reduces the numbers of neutrophils in infected lungs.",10.1101/2025.10.13.682000,1.0
anti-CD44,anti-CD44,reduce,"With flow cytometry, we show that anti-CD44 reduces the numbers of neutrophils in infected lungs.",10.1101/2025.10.13.682000,1.0
anti-CD44,anti-CD44,reduce,"With flow cytometry, we show that anti-CD44 reduces the numbers of neutrophils in infected lungs.",10.1101/2025.10.13.682000,1.0
anti-CD44,anti-CD44,reduce,"With flow cytometry, we show that anti-CD44 reduces the numbers of neutrophils in infected lungs.",10.1101/2025.10.13.682000,1.0
anti-CD44,anti-CD44,reduce,"We also show through immunofluorescence that treatment with anti-CD44 antibodies reduces colocalization of HA and CD45 in lung sections, indicating that HAs interaction with immune cells contributes to pathology.",10.1101/2025.10.13.682000,1.0
anti-CD44,anti-CD44,reduce,"We also show through immunofluorescence that treatment with anti-CD44 antibodies reduces colocalization of HA and CD45 in lung sections, indicating that HAs interaction with immune cells contributes to pathology.",10.1101/2025.10.13.682000,1.0
anti-CD44,anti-CD44,reduce,"We also show through immunofluorescence that treatment with anti-CD44 antibodies reduces colocalization of HA and CD45 in lung sections, indicating that HAs interaction with immune cells contributes to pathology.",10.1101/2025.10.13.682000,1.0
anti-CD44,anti-CD44,reduce,"We also show through immunofluorescence that treatment with anti-CD44 antibodies reduces colocalization of HA and CD45 in lung sections, indicating that HAs interaction with immune cells contributes to pathology.",10.1101/2025.10.13.682000,1.0
anti-CD44,anti-CD44,reduce,"We also show through immunofluorescence that treatment with anti-CD44 antibodies reduces colocalization of HA and CD45 in lung sections, indicating that HAs interaction with immune cells contributes to pathology.",10.1101/2025.10.13.682000,1.0
anti-CD44,anti-CD44,reduce,"We also show through immunofluorescence that treatment with anti-CD44 antibodies reduces colocalization of HA and CD45 in lung sections, indicating that HAs interaction with immune cells contributes to pathology.",10.1101/2025.10.13.682000,1.0
infection,infection,prevent,Our findings demonstrate that disruption of HA-receptor interactions is a way to prevent inflammatory pathology in pulmonary infection.,10.1101/2025.10.13.682000,1.0
pulmonary infection,infection,prevent,Our findings demonstrate that disruption of HA-receptor interactions is a way to prevent inflammatory pathology in pulmonary infection.,10.1101/2025.10.13.682000,0.5
pulmonary infection,infection,prevent,Our findings demonstrate that disruption of HA-receptor interactions is a way to prevent inflammatory pathology in pulmonary infection.,10.1101/2025.10.13.682000,0.5
mucormycosis,diabetes,increase,"During COVID-19 pandemic, the cases of mucormycosis increased substantially, with rhino-orbito-cerebral form linked to uncontrolled diabetes being the predominant manifestation.",10.1101/2025.10.13.681985,0.09090909090909091
mucormycosis,mucormycosis,increase,"During COVID-19 pandemic, the cases of mucormycosis increased substantially, with rhino-orbito-cerebral form linked to uncontrolled diabetes being the predominant manifestation.",10.1101/2025.10.13.681985,1.0
mucormycosis,mucormycosis,increase,"During COVID-19 pandemic, the cases of mucormycosis increased substantially, with rhino-orbito-cerebral form linked to uncontrolled diabetes being the predominant manifestation.",10.1101/2025.10.13.681985,1.0
mucormycosis,mucormycosis,increase,"During COVID-19 pandemic, the cases of mucormycosis increased substantially, with rhino-orbito-cerebral form linked to uncontrolled diabetes being the predominant manifestation.",10.1101/2025.10.13.681985,1.0
mucormycosis,mucormycosis,increase,"During COVID-19 pandemic, the cases of mucormycosis increased substantially, with rhino-orbito-cerebral form linked to uncontrolled diabetes being the predominant manifestation.",10.1101/2025.10.13.681985,1.0
mucormycosis,diabetes,increase,"During COVID-19 pandemic, the cases of mucormycosis increased substantially, with rhino-orbito-cerebral form linked to uncontrolled diabetes being the predominant manifestation.",10.1101/2025.10.13.681985,0.09090909090909091
mucormycosis,diabetes,increase,"During COVID-19 pandemic, the cases of mucormycosis increased substantially, with rhino-orbito-cerebral form linked to uncontrolled diabetes being the predominant manifestation.",10.1101/2025.10.13.681985,0.09090909090909091
mucormycosis,diabetes,increase,"During COVID-19 pandemic, the cases of mucormycosis increased substantially, with rhino-orbito-cerebral form linked to uncontrolled diabetes being the predominant manifestation.",10.1101/2025.10.13.681985,0.09090909090909091
mucormycosis,diabetes,increase,"During COVID-19 pandemic, the cases of mucormycosis increased substantially, with rhino-orbito-cerebral form linked to uncontrolled diabetes being the predominant manifestation.",10.1101/2025.10.13.681985,0.09090909090909091
mucormycosis,mucormycosis,increase,"During COVID-19 pandemic, the cases of mucormycosis increased substantially, with rhino-orbito-cerebral form linked to uncontrolled diabetes being the predominant manifestation.",10.1101/2025.10.13.681985,1.0
mucormycosis,mucormycosis,increase,"During COVID-19 pandemic, the cases of mucormycosis increased substantially, with rhino-orbito-cerebral form linked to uncontrolled diabetes being the predominant manifestation.",10.1101/2025.10.13.681985,1.0
mucormycosis,mucormycosis,increase,"During COVID-19 pandemic, the cases of mucormycosis increased substantially, with rhino-orbito-cerebral form linked to uncontrolled diabetes being the predominant manifestation.",10.1101/2025.10.13.681985,1.0
mucormycosis,mucormycosis,increase,"During COVID-19 pandemic, the cases of mucormycosis increased substantially, with rhino-orbito-cerebral form linked to uncontrolled diabetes being the predominant manifestation.",10.1101/2025.10.13.681985,1.0
mucormycosis,mucormycosis,increase,"During COVID-19 pandemic, the cases of mucormycosis increased substantially, with rhino-orbito-cerebral form linked to uncontrolled diabetes being the predominant manifestation.",10.1101/2025.10.13.681985,1.0
mucormycosis,mucormycosis,increase,"During COVID-19 pandemic, the cases of mucormycosis increased substantially, with rhino-orbito-cerebral form linked to uncontrolled diabetes being the predominant manifestation.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,0.1111111111111111
mucormycosis,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,0.1111111111111111
mucormycosis,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,0.1111111111111111
zinc,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,0.1111111111111111
zinc,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,0.1111111111111111
mucormycosis,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,1.0
mucormycosis,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,0.1111111111111111
zinc,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,0.1111111111111111
zinc,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,0.1111111111111111
zinc,zinc,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,0.1111111111111111
zinc,zinc,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,1.0
zinc,zinc,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,1.0
zinc,zinc,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,0.1111111111111111
zinc,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,0.1111111111111111
zinc,zinc,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,1.0
zinc,zinc,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,0.1111111111111111
mucormycosis,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,0.1111111111111111
zinc,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,0.1111111111111111
zinc,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,0.1111111111111111
mucormycosis,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,1.0
mucormycosis,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,0.1111111111111111
zinc,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,0.1111111111111111
zinc,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,0.1111111111111111
zinc,zinc,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,1.0
zinc,zinc,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,1.0
zinc,zinc,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,0.1111111111111111
zinc,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,0.1111111111111111
zinc,zinc,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,1.0
zinc,zinc,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,0.1111111111111111
zinc,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,0.1111111111111111
zinc,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,0.1111111111111111
mucormycosis,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,1.0
mucormycosis,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,0.1111111111111111
zinc,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,0.1111111111111111
zinc,zinc,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,1.0
zinc,zinc,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,0.1111111111111111
zinc,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,0.1111111111111111
zinc,zinc,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,1.0
zinc,zinc,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,1.0
zinc,zinc,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,0.1111111111111111
zinc,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,0.1111111111111111
zinc,zinc,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,1.0
zinc,zinc,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,0.1111111111111111
zinc,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,0.1111111111111111
zinc,zinc,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,1.0
zinc,zinc,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,1.0
mucormycosis,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,0.1111111111111111
zinc,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,0.1111111111111111
zinc,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,0.1111111111111111
zinc,mucormycosis,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,0.1111111111111111
zinc,zinc,associate,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.08333333333333333
mucormycosis,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.08333333333333333
Rhizopus arrhizus,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.1111111111111111
mucormycosis,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.08333333333333333
zinc,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.08333333333333333
zinc,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.08333333333333333
mucormycosis,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,1.0
mucormycosis,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.08333333333333333
zinc,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.08333333333333333
zinc,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.08333333333333333
zinc,zinc,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,Rhizopus arrhizus,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.25
zinc,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.08333333333333333
zinc,zinc,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,zinc,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,zinc,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.08333333333333333
zinc,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.08333333333333333
zinc,zinc,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,zinc,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.08333333333333333
Rhizopus arrhizus,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.1111111111111111
mucormycosis,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.08333333333333333
zinc,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.08333333333333333
zinc,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.08333333333333333
mucormycosis,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,1.0
mucormycosis,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.08333333333333333
zinc,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.08333333333333333
zinc,Rhizopus arrhizus,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.25
zinc,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.08333333333333333
zinc,zinc,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,zinc,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,zinc,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.08333333333333333
zinc,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.08333333333333333
zinc,zinc,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,zinc,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,1.0
Rhizopus arrhizus,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.1111111111111111
zinc,Rhizopus arrhizus,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.25
zinc,Rhizopus arrhizus,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.25
zinc,Rhizopus arrhizus,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.25
Rhizopus arrhizus,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.1111111111111111
Rhizopus arrhizus,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.1111111111111111
zinc,Rhizopus arrhizus,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.25
zinc,Rhizopus arrhizus,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.25
zinc,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.08333333333333333
zinc,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.08333333333333333
zinc,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.08333333333333333
mucormycosis,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,1.0
mucormycosis,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.08333333333333333
zinc,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.08333333333333333
zinc,zinc,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,zinc,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.08333333333333333
zinc,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.08333333333333333
zinc,zinc,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,zinc,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,zinc,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.08333333333333333
zinc,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.08333333333333333
zinc,zinc,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,zinc,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.08333333333333333
zinc,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.08333333333333333
zinc,zinc,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,zinc,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,1.0
mucormycosis,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.08333333333333333
zinc,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.08333333333333333
zinc,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.08333333333333333
zinc,mucormycosis,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,0.08333333333333333
zinc,zinc,elucidate,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,zinc,evaluate,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985,1.0
zinc,hydrogen peroxide,evaluate,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985,0.03125
zinc,sodium chloride,evaluate,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985,0.02631578947368421
zinc,zinc,evaluate,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985,1.0
zinc,zinc,evaluate,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985,1.0
zinc,zinc,evaluate,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985,1.0
zinc,zinc,evaluate,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985,1.0
zinc,zinc,evaluate,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985,1.0
zinc,hydrogen peroxide,evaluate,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985,0.03125
zinc,sodium chloride,evaluate,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985,0.02631578947368421
zinc,zinc,evaluate,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985,1.0
zinc,zinc,evaluate,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985,1.0
zinc,zinc,evaluate,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985,1.0
zinc,zinc,evaluate,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985,1.0
zinc,zinc,evaluate,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985,1.0
hydrogen peroxide,sodium chloride,evaluate,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985,0.14285714285714285
zinc,hydrogen peroxide,evaluate,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985,0.03125
zinc,hydrogen peroxide,evaluate,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985,0.03125
zinc,hydrogen peroxide,evaluate,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985,0.03125
zinc,hydrogen peroxide,evaluate,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985,0.03125
zinc,hydrogen peroxide,evaluate,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985,0.03125
zinc,sodium chloride,evaluate,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985,0.02631578947368421
zinc,sodium chloride,evaluate,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985,0.02631578947368421
zinc,sodium chloride,evaluate,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985,0.02631578947368421
zinc,sodium chloride,evaluate,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985,0.02631578947368421
zinc,sodium chloride,evaluate,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985,0.02631578947368421
zinc,zinc,evaluate,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985,1.0
zinc,zinc,evaluate,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985,1.0
zinc,zinc,evaluate,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985,1.0
zinc,zinc,evaluate,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985,1.0
zinc,zinc,evaluate,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985,1.0
zinc,zinc,evaluate,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985,1.0
zinc,zinc,evaluate,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985,1.0
zinc,zinc,evaluate,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985,1.0
zinc,zinc,evaluate,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985,1.0
zinc,zinc,evaluate,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985,1.0
zinc,zinc,enhance,"Exposure to zinc enhanced the metabolic activity, and partly alleviated the cell-wall and oxidative stress.",10.1101/2025.10.13.681985,1.0
zinc,zinc,enhance,"Exposure to zinc enhanced the metabolic activity, and partly alleviated the cell-wall and oxidative stress.",10.1101/2025.10.13.681985,1.0
zinc,zinc,enhance,"Exposure to zinc enhanced the metabolic activity, and partly alleviated the cell-wall and oxidative stress.",10.1101/2025.10.13.681985,1.0
zinc,zinc,enhance,"Exposure to zinc enhanced the metabolic activity, and partly alleviated the cell-wall and oxidative stress.",10.1101/2025.10.13.681985,1.0
zinc,zinc,enhance,"Exposure to zinc enhanced the metabolic activity, and partly alleviated the cell-wall and oxidative stress.",10.1101/2025.10.13.681985,1.0
zinc,zinc,enhance,"Exposure to zinc enhanced the metabolic activity, and partly alleviated the cell-wall and oxidative stress.",10.1101/2025.10.13.681985,1.0
zinc,zinc,enhance,"Exposure to zinc enhanced the metabolic activity, and partly alleviated the cell-wall and oxidative stress.",10.1101/2025.10.13.681985,1.0
zinc,zinc,enhance,"Exposure to zinc enhanced the metabolic activity, and partly alleviated the cell-wall and oxidative stress.",10.1101/2025.10.13.681985,1.0
zinc,zinc,enhance,"Exposure to zinc enhanced the metabolic activity, and partly alleviated the cell-wall and oxidative stress.",10.1101/2025.10.13.681985,1.0
zinc,zinc,enhance,"Exposure to zinc enhanced the metabolic activity, and partly alleviated the cell-wall and oxidative stress.",10.1101/2025.10.13.681985,1.0
zinc,zinc,enhance,"Exposure to zinc enhanced the metabolic activity, and partly alleviated the cell-wall and oxidative stress.",10.1101/2025.10.13.681985,1.0
zinc,zinc,enhance,"Exposure to zinc enhanced the metabolic activity, and partly alleviated the cell-wall and oxidative stress.",10.1101/2025.10.13.681985,1.0
zinc,zinc,enhance,"Exposure to zinc enhanced the metabolic activity, and partly alleviated the cell-wall and oxidative stress.",10.1101/2025.10.13.681985,1.0
zinc,zinc,enhance,"Exposure to zinc enhanced the metabolic activity, and partly alleviated the cell-wall and oxidative stress.",10.1101/2025.10.13.681985,1.0
zinc,zinc,enhance,"Exposure to zinc enhanced the metabolic activity, and partly alleviated the cell-wall and oxidative stress.",10.1101/2025.10.13.681985,1.0
zinc,zinc,enhance,"Exposure to zinc enhanced the metabolic activity, and partly alleviated the cell-wall and oxidative stress.",10.1101/2025.10.13.681985,1.0
zinc,zinc,enhance,"Exposure to zinc enhanced the metabolic activity, and partly alleviated the cell-wall and oxidative stress.",10.1101/2025.10.13.681985,1.0
zinc,zinc,enhance,"Exposure to zinc enhanced the metabolic activity, and partly alleviated the cell-wall and oxidative stress.",10.1101/2025.10.13.681985,1.0
zinc,zinc,enhance,"Exposure to zinc enhanced the metabolic activity, and partly alleviated the cell-wall and oxidative stress.",10.1101/2025.10.13.681985,1.0
zinc,zinc,enhance,"Exposure to zinc enhanced the metabolic activity, and partly alleviated the cell-wall and oxidative stress.",10.1101/2025.10.13.681985,1.0
zinc,zinc,enhance,"Exposure to zinc enhanced the metabolic activity, and partly alleviated the cell-wall and oxidative stress.",10.1101/2025.10.13.681985,1.0
amphotericin B,posaconazole,unknown,Susceptibility to amphotericin B and posaconazole was unchanged.,10.1101/2025.10.13.681985,0.25
ergosterol,chitosan,associate,"Zinc-supplemented cultures over-expressed multiple genes, notably those associated with respiratory electron transport chain, ergosterol biosynthesis, chitosan production, oxidative stress response, mucoricin, high-affinity iron permease, iron transport multi-copper oxidase and ferric-reductase-like protein.",10.1101/2025.10.13.681985,0.25
ergosterol,iron,associate,"Zinc-supplemented cultures over-expressed multiple genes, notably those associated with respiratory electron transport chain, ergosterol biosynthesis, chitosan production, oxidative stress response, mucoricin, high-affinity iron permease, iron transport multi-copper oxidase and ferric-reductase-like protein.",10.1101/2025.10.13.681985,0.07142857142857142
ergosterol,iron,associate,"Zinc-supplemented cultures over-expressed multiple genes, notably those associated with respiratory electron transport chain, ergosterol biosynthesis, chitosan production, oxidative stress response, mucoricin, high-affinity iron permease, iron transport multi-copper oxidase and ferric-reductase-like protein.",10.1101/2025.10.13.681985,0.07142857142857142
ergosterol,iron,associate,"Zinc-supplemented cultures over-expressed multiple genes, notably those associated with respiratory electron transport chain, ergosterol biosynthesis, chitosan production, oxidative stress response, mucoricin, high-affinity iron permease, iron transport multi-copper oxidase and ferric-reductase-like protein.",10.1101/2025.10.13.681985,0.07142857142857142
chitosan,iron,associate,"Zinc-supplemented cultures over-expressed multiple genes, notably those associated with respiratory electron transport chain, ergosterol biosynthesis, chitosan production, oxidative stress response, mucoricin, high-affinity iron permease, iron transport multi-copper oxidase and ferric-reductase-like protein.",10.1101/2025.10.13.681985,0.09090909090909091
chitosan,iron,associate,"Zinc-supplemented cultures over-expressed multiple genes, notably those associated with respiratory electron transport chain, ergosterol biosynthesis, chitosan production, oxidative stress response, mucoricin, high-affinity iron permease, iron transport multi-copper oxidase and ferric-reductase-like protein.",10.1101/2025.10.13.681985,0.09090909090909091
chitosan,iron,associate,"Zinc-supplemented cultures over-expressed multiple genes, notably those associated with respiratory electron transport chain, ergosterol biosynthesis, chitosan production, oxidative stress response, mucoricin, high-affinity iron permease, iron transport multi-copper oxidase and ferric-reductase-like protein.",10.1101/2025.10.13.681985,0.09090909090909091
iron,iron,associate,"Zinc-supplemented cultures over-expressed multiple genes, notably those associated with respiratory electron transport chain, ergosterol biosynthesis, chitosan production, oxidative stress response, mucoricin, high-affinity iron permease, iron transport multi-copper oxidase and ferric-reductase-like protein.",10.1101/2025.10.13.681985,1.0
iron,iron,associate,"Zinc-supplemented cultures over-expressed multiple genes, notably those associated with respiratory electron transport chain, ergosterol biosynthesis, chitosan production, oxidative stress response, mucoricin, high-affinity iron permease, iron transport multi-copper oxidase and ferric-reductase-like protein.",10.1101/2025.10.13.681985,1.0
iron,iron,associate,"Zinc-supplemented cultures over-expressed multiple genes, notably those associated with respiratory electron transport chain, ergosterol biosynthesis, chitosan production, oxidative stress response, mucoricin, high-affinity iron permease, iron transport multi-copper oxidase and ferric-reductase-like protein.",10.1101/2025.10.13.681985,1.0
Candida albicans,Candida albicans,augment,Zinc also augmented the growth/metabolism of several other Mucorales but not Aspergillus fumigatus and Candida albicans.,10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,0.03225806451612903
mucormycosis,mucormycosis,contribute,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,0.03225806451612903
mucormycosis,mucormycosis,contribute,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,0.03225806451612903
zinc,mucormycosis,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,0.03225806451612903
zinc,mucormycosis,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,0.03225806451612903
mucormycosis,mucormycosis,contribute,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,1.0
mucormycosis,mucormycosis,contribute,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,0.03225806451612903
zinc,mucormycosis,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,0.03225806451612903
zinc,mucormycosis,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,0.03225806451612903
zinc,zinc,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,0.03225806451612903
zinc,zinc,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,zinc,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,zinc,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,0.03225806451612903
zinc,mucormycosis,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,0.03225806451612903
zinc,zinc,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,zinc,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,0.03225806451612903
mucormycosis,mucormycosis,contribute,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,0.03225806451612903
zinc,mucormycosis,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,0.03225806451612903
zinc,mucormycosis,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,0.03225806451612903
mucormycosis,mucormycosis,contribute,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,1.0
mucormycosis,mucormycosis,contribute,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,0.03225806451612903
zinc,mucormycosis,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,0.03225806451612903
zinc,mucormycosis,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,0.03225806451612903
zinc,zinc,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,zinc,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,zinc,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,0.03225806451612903
zinc,mucormycosis,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,0.03225806451612903
zinc,zinc,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,zinc,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,0.03225806451612903
zinc,mucormycosis,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,0.03225806451612903
zinc,mucormycosis,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,0.03225806451612903
mucormycosis,mucormycosis,contribute,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,1.0
mucormycosis,mucormycosis,contribute,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,0.03225806451612903
zinc,mucormycosis,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,0.03225806451612903
zinc,zinc,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,zinc,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,0.03225806451612903
zinc,mucormycosis,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,0.03225806451612903
zinc,zinc,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,zinc,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,zinc,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,0.03225806451612903
zinc,mucormycosis,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,0.03225806451612903
zinc,zinc,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,zinc,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,0.03225806451612903
zinc,mucormycosis,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,0.03225806451612903
zinc,zinc,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,zinc,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,1.0
mucormycosis,mucormycosis,contribute,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,1.0
zinc,mucormycosis,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,0.03225806451612903
zinc,mucormycosis,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,0.03225806451612903
zinc,mucormycosis,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,0.03225806451612903
zinc,mucormycosis,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,0.03225806451612903
zinc,zinc,support,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985,1.0
mucormycosis,mucormycosis,implicate,"Several risk factors were implicated in the emergence of COVID-19 associated mucormycosis (CAM), including inappropriate corticosteroid usage and COVID-19 associated glycemic imbalance.",10.1101/2025.10.13.681985,1.0
mucormycosis,mucormycosis,implicate,"Several risk factors were implicated in the emergence of COVID-19 associated mucormycosis (CAM), including inappropriate corticosteroid usage and COVID-19 associated glycemic imbalance.",10.1101/2025.10.13.681985,1.0
mucormycosis,mucormycosis,implicate,"Several risk factors were implicated in the emergence of COVID-19 associated mucormycosis (CAM), including inappropriate corticosteroid usage and COVID-19 associated glycemic imbalance.",10.1101/2025.10.13.681985,1.0
mucormycosis,mucormycosis,implicate,"Several risk factors were implicated in the emergence of COVID-19 associated mucormycosis (CAM), including inappropriate corticosteroid usage and COVID-19 associated glycemic imbalance.",10.1101/2025.10.13.681985,1.0
mucormycosis,mucormycosis,implicate,"Several risk factors were implicated in the emergence of COVID-19 associated mucormycosis (CAM), including inappropriate corticosteroid usage and COVID-19 associated glycemic imbalance.",10.1101/2025.10.13.681985,1.0
mucormycosis,mucormycosis,implicate,"Several risk factors were implicated in the emergence of COVID-19 associated mucormycosis (CAM), including inappropriate corticosteroid usage and COVID-19 associated glycemic imbalance.",10.1101/2025.10.13.681985,1.0
mucormycosis,mucormycosis,implicate,"Several risk factors were implicated in the emergence of COVID-19 associated mucormycosis (CAM), including inappropriate corticosteroid usage and COVID-19 associated glycemic imbalance.",10.1101/2025.10.13.681985,1.0
mucormycosis,mucormycosis,implicate,"Several risk factors were implicated in the emergence of COVID-19 associated mucormycosis (CAM), including inappropriate corticosteroid usage and COVID-19 associated glycemic imbalance.",10.1101/2025.10.13.681985,1.0
mucormycosis,mucormycosis,implicate,"Several risk factors were implicated in the emergence of COVID-19 associated mucormycosis (CAM), including inappropriate corticosteroid usage and COVID-19 associated glycemic imbalance.",10.1101/2025.10.13.681985,1.0
mucormycosis,mucormycosis,implicate,"Several risk factors were implicated in the emergence of COVID-19 associated mucormycosis (CAM), including inappropriate corticosteroid usage and COVID-19 associated glycemic imbalance.",10.1101/2025.10.13.681985,1.0
zinc,zinc,propose,"The excessive intake of nutritional supplements, especially that of zinc, owing to self-medication and over-prescription, was also proposed as a plausible factor in the rise of CAM in many clinical/epidemiological studies.",10.1101/2025.10.13.681985,1.0
zinc,zinc,propose,"The excessive intake of nutritional supplements, especially that of zinc, owing to self-medication and over-prescription, was also proposed as a plausible factor in the rise of CAM in many clinical/epidemiological studies.",10.1101/2025.10.13.681985,1.0
zinc,zinc,propose,"The excessive intake of nutritional supplements, especially that of zinc, owing to self-medication and over-prescription, was also proposed as a plausible factor in the rise of CAM in many clinical/epidemiological studies.",10.1101/2025.10.13.681985,1.0
zinc,zinc,propose,"The excessive intake of nutritional supplements, especially that of zinc, owing to self-medication and over-prescription, was also proposed as a plausible factor in the rise of CAM in many clinical/epidemiological studies.",10.1101/2025.10.13.681985,1.0
zinc,zinc,propose,"The excessive intake of nutritional supplements, especially that of zinc, owing to self-medication and over-prescription, was also proposed as a plausible factor in the rise of CAM in many clinical/epidemiological studies.",10.1101/2025.10.13.681985,1.0
zinc,zinc,propose,"The excessive intake of nutritional supplements, especially that of zinc, owing to self-medication and over-prescription, was also proposed as a plausible factor in the rise of CAM in many clinical/epidemiological studies.",10.1101/2025.10.13.681985,1.0
zinc,zinc,propose,"The excessive intake of nutritional supplements, especially that of zinc, owing to self-medication and over-prescription, was also proposed as a plausible factor in the rise of CAM in many clinical/epidemiological studies.",10.1101/2025.10.13.681985,1.0
zinc,zinc,propose,"The excessive intake of nutritional supplements, especially that of zinc, owing to self-medication and over-prescription, was also proposed as a plausible factor in the rise of CAM in many clinical/epidemiological studies.",10.1101/2025.10.13.681985,1.0
zinc,zinc,propose,"The excessive intake of nutritional supplements, especially that of zinc, owing to self-medication and over-prescription, was also proposed as a plausible factor in the rise of CAM in many clinical/epidemiological studies.",10.1101/2025.10.13.681985,1.0
zinc,zinc,propose,"The excessive intake of nutritional supplements, especially that of zinc, owing to self-medication and over-prescription, was also proposed as a plausible factor in the rise of CAM in many clinical/epidemiological studies.",10.1101/2025.10.13.681985,1.0
zinc,zinc,propose,"The excessive intake of nutritional supplements, especially that of zinc, owing to self-medication and over-prescription, was also proposed as a plausible factor in the rise of CAM in many clinical/epidemiological studies.",10.1101/2025.10.13.681985,1.0
zinc,zinc,propose,"The excessive intake of nutritional supplements, especially that of zinc, owing to self-medication and over-prescription, was also proposed as a plausible factor in the rise of CAM in many clinical/epidemiological studies.",10.1101/2025.10.13.681985,1.0
zinc,zinc,propose,"The excessive intake of nutritional supplements, especially that of zinc, owing to self-medication and over-prescription, was also proposed as a plausible factor in the rise of CAM in many clinical/epidemiological studies.",10.1101/2025.10.13.681985,1.0
zinc,zinc,propose,"The excessive intake of nutritional supplements, especially that of zinc, owing to self-medication and over-prescription, was also proposed as a plausible factor in the rise of CAM in many clinical/epidemiological studies.",10.1101/2025.10.13.681985,1.0
zinc,zinc,propose,"The excessive intake of nutritional supplements, especially that of zinc, owing to self-medication and over-prescription, was also proposed as a plausible factor in the rise of CAM in many clinical/epidemiological studies.",10.1101/2025.10.13.681985,1.0
zinc,zinc,propose,"The excessive intake of nutritional supplements, especially that of zinc, owing to self-medication and over-prescription, was also proposed as a plausible factor in the rise of CAM in many clinical/epidemiological studies.",10.1101/2025.10.13.681985,1.0
zinc,zinc,propose,"The excessive intake of nutritional supplements, especially that of zinc, owing to self-medication and over-prescription, was also proposed as a plausible factor in the rise of CAM in many clinical/epidemiological studies.",10.1101/2025.10.13.681985,1.0
zinc,zinc,propose,"The excessive intake of nutritional supplements, especially that of zinc, owing to self-medication and over-prescription, was also proposed as a plausible factor in the rise of CAM in many clinical/epidemiological studies.",10.1101/2025.10.13.681985,1.0
zinc,zinc,propose,"The excessive intake of nutritional supplements, especially that of zinc, owing to self-medication and over-prescription, was also proposed as a plausible factor in the rise of CAM in many clinical/epidemiological studies.",10.1101/2025.10.13.681985,1.0
zinc,zinc,propose,"The excessive intake of nutritional supplements, especially that of zinc, owing to self-medication and over-prescription, was also proposed as a plausible factor in the rise of CAM in many clinical/epidemiological studies.",10.1101/2025.10.13.681985,1.0
zinc,zinc,propose,"The excessive intake of nutritional supplements, especially that of zinc, owing to self-medication and over-prescription, was also proposed as a plausible factor in the rise of CAM in many clinical/epidemiological studies.",10.1101/2025.10.13.681985,1.0
zinc,zinc,evaluate,This study experimentally evaluated the potential impact of zinc enrichment on pathogenic Mucorales.,10.1101/2025.10.13.681985,1.0
zinc,zinc,evaluate,This study experimentally evaluated the potential impact of zinc enrichment on pathogenic Mucorales.,10.1101/2025.10.13.681985,1.0
zinc,zinc,evaluate,This study experimentally evaluated the potential impact of zinc enrichment on pathogenic Mucorales.,10.1101/2025.10.13.681985,1.0
zinc,zinc,evaluate,This study experimentally evaluated the potential impact of zinc enrichment on pathogenic Mucorales.,10.1101/2025.10.13.681985,1.0
zinc,zinc,evaluate,This study experimentally evaluated the potential impact of zinc enrichment on pathogenic Mucorales.,10.1101/2025.10.13.681985,1.0
zinc,zinc,evaluate,This study experimentally evaluated the potential impact of zinc enrichment on pathogenic Mucorales.,10.1101/2025.10.13.681985,1.0
zinc,zinc,evaluate,This study experimentally evaluated the potential impact of zinc enrichment on pathogenic Mucorales.,10.1101/2025.10.13.681985,1.0
zinc,zinc,evaluate,This study experimentally evaluated the potential impact of zinc enrichment on pathogenic Mucorales.,10.1101/2025.10.13.681985,1.0
zinc,zinc,evaluate,This study experimentally evaluated the potential impact of zinc enrichment on pathogenic Mucorales.,10.1101/2025.10.13.681985,1.0
zinc,zinc,evaluate,This study experimentally evaluated the potential impact of zinc enrichment on pathogenic Mucorales.,10.1101/2025.10.13.681985,1.0
zinc,zinc,evaluate,This study experimentally evaluated the potential impact of zinc enrichment on pathogenic Mucorales.,10.1101/2025.10.13.681985,1.0
zinc,zinc,evaluate,This study experimentally evaluated the potential impact of zinc enrichment on pathogenic Mucorales.,10.1101/2025.10.13.681985,1.0
zinc,zinc,evaluate,This study experimentally evaluated the potential impact of zinc enrichment on pathogenic Mucorales.,10.1101/2025.10.13.681985,1.0
zinc,zinc,evaluate,This study experimentally evaluated the potential impact of zinc enrichment on pathogenic Mucorales.,10.1101/2025.10.13.681985,1.0
zinc,zinc,evaluate,This study experimentally evaluated the potential impact of zinc enrichment on pathogenic Mucorales.,10.1101/2025.10.13.681985,1.0
zinc,zinc,evaluate,This study experimentally evaluated the potential impact of zinc enrichment on pathogenic Mucorales.,10.1101/2025.10.13.681985,1.0
zinc,zinc,evaluate,This study experimentally evaluated the potential impact of zinc enrichment on pathogenic Mucorales.,10.1101/2025.10.13.681985,1.0
zinc,zinc,evaluate,This study experimentally evaluated the potential impact of zinc enrichment on pathogenic Mucorales.,10.1101/2025.10.13.681985,1.0
zinc,zinc,evaluate,This study experimentally evaluated the potential impact of zinc enrichment on pathogenic Mucorales.,10.1101/2025.10.13.681985,1.0
zinc,zinc,evaluate,This study experimentally evaluated the potential impact of zinc enrichment on pathogenic Mucorales.,10.1101/2025.10.13.681985,1.0
zinc,zinc,evaluate,This study experimentally evaluated the potential impact of zinc enrichment on pathogenic Mucorales.,10.1101/2025.10.13.681985,1.0
zinc,zinc,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,1.0
zinc,Rhizopus arrhizus,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,0.25
zinc,zinc,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,1.0
zinc,iron,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,0.04
zinc,iron,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,0.04
zinc,zinc,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,1.0
zinc,zinc,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,1.0
zinc,zinc,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,1.0
zinc,iron,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,0.04
zinc,zinc,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,1.0
zinc,Rhizopus arrhizus,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,0.25
zinc,zinc,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,1.0
zinc,iron,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,0.04
zinc,iron,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,0.04
zinc,zinc,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,1.0
zinc,zinc,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,1.0
zinc,zinc,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,1.0
zinc,iron,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,0.04
zinc,zinc,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,1.0
zinc,Rhizopus arrhizus,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,0.25
Rhizopus arrhizus,iron,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,0.045454545454545456
Rhizopus arrhizus,iron,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,0.045454545454545456
zinc,Rhizopus arrhizus,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,0.25
zinc,Rhizopus arrhizus,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,0.25
zinc,Rhizopus arrhizus,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,0.25
Rhizopus arrhizus,iron,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,0.045454545454545456
zinc,Rhizopus arrhizus,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,0.25
zinc,iron,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,0.04
zinc,iron,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,0.04
zinc,zinc,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,1.0
zinc,zinc,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,1.0
zinc,zinc,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,1.0
zinc,iron,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,0.04
zinc,zinc,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,1.0
iron,iron,enhance,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,1.0
zinc,iron,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,0.04
zinc,iron,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,0.04
zinc,iron,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,0.04
iron,iron,enhance,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,1.0
zinc,iron,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,0.04
zinc,iron,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,0.04
zinc,iron,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,0.04
zinc,iron,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,0.04
iron,iron,enhance,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,1.0
zinc,iron,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,0.04
zinc,zinc,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,1.0
zinc,zinc,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,1.0
zinc,iron,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,0.04
zinc,zinc,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,1.0
zinc,zinc,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,1.0
zinc,iron,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,0.04
zinc,zinc,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,1.0
zinc,iron,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,0.04
zinc,zinc,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,1.0
zinc,iron,support,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985,0.04
Candida albicans,Candida albicans,observe,"Notably, the augmentation was specifically observed in pathogenic Mucorales but not Aspergillus fumigatus and Candida albicans.",10.1101/2025.10.13.681985,1.0
zinc,zinc,provide,"The work provides experimental evidence for the potential association of zinc over-availability with the occurrence of CAM, and strengthens evidence-based therapeutic practices in clinical settings.",10.1101/2025.10.13.681985,1.0
zinc,zinc,provide,"The work provides experimental evidence for the potential association of zinc over-availability with the occurrence of CAM, and strengthens evidence-based therapeutic practices in clinical settings.",10.1101/2025.10.13.681985,1.0
zinc,zinc,provide,"The work provides experimental evidence for the potential association of zinc over-availability with the occurrence of CAM, and strengthens evidence-based therapeutic practices in clinical settings.",10.1101/2025.10.13.681985,1.0
zinc,zinc,provide,"The work provides experimental evidence for the potential association of zinc over-availability with the occurrence of CAM, and strengthens evidence-based therapeutic practices in clinical settings.",10.1101/2025.10.13.681985,1.0
zinc,zinc,provide,"The work provides experimental evidence for the potential association of zinc over-availability with the occurrence of CAM, and strengthens evidence-based therapeutic practices in clinical settings.",10.1101/2025.10.13.681985,1.0
zinc,zinc,provide,"The work provides experimental evidence for the potential association of zinc over-availability with the occurrence of CAM, and strengthens evidence-based therapeutic practices in clinical settings.",10.1101/2025.10.13.681985,1.0
zinc,zinc,provide,"The work provides experimental evidence for the potential association of zinc over-availability with the occurrence of CAM, and strengthens evidence-based therapeutic practices in clinical settings.",10.1101/2025.10.13.681985,1.0
zinc,zinc,provide,"The work provides experimental evidence for the potential association of zinc over-availability with the occurrence of CAM, and strengthens evidence-based therapeutic practices in clinical settings.",10.1101/2025.10.13.681985,1.0
zinc,zinc,provide,"The work provides experimental evidence for the potential association of zinc over-availability with the occurrence of CAM, and strengthens evidence-based therapeutic practices in clinical settings.",10.1101/2025.10.13.681985,1.0
zinc,zinc,provide,"The work provides experimental evidence for the potential association of zinc over-availability with the occurrence of CAM, and strengthens evidence-based therapeutic practices in clinical settings.",10.1101/2025.10.13.681985,1.0
zinc,zinc,provide,"The work provides experimental evidence for the potential association of zinc over-availability with the occurrence of CAM, and strengthens evidence-based therapeutic practices in clinical settings.",10.1101/2025.10.13.681985,1.0
zinc,zinc,provide,"The work provides experimental evidence for the potential association of zinc over-availability with the occurrence of CAM, and strengthens evidence-based therapeutic practices in clinical settings.",10.1101/2025.10.13.681985,1.0
zinc,zinc,provide,"The work provides experimental evidence for the potential association of zinc over-availability with the occurrence of CAM, and strengthens evidence-based therapeutic practices in clinical settings.",10.1101/2025.10.13.681985,1.0
zinc,zinc,provide,"The work provides experimental evidence for the potential association of zinc over-availability with the occurrence of CAM, and strengthens evidence-based therapeutic practices in clinical settings.",10.1101/2025.10.13.681985,1.0
zinc,zinc,provide,"The work provides experimental evidence for the potential association of zinc over-availability with the occurrence of CAM, and strengthens evidence-based therapeutic practices in clinical settings.",10.1101/2025.10.13.681985,1.0
zinc,zinc,provide,"The work provides experimental evidence for the potential association of zinc over-availability with the occurrence of CAM, and strengthens evidence-based therapeutic practices in clinical settings.",10.1101/2025.10.13.681985,1.0
zinc,zinc,provide,"The work provides experimental evidence for the potential association of zinc over-availability with the occurrence of CAM, and strengthens evidence-based therapeutic practices in clinical settings.",10.1101/2025.10.13.681985,1.0
zinc,zinc,provide,"The work provides experimental evidence for the potential association of zinc over-availability with the occurrence of CAM, and strengthens evidence-based therapeutic practices in clinical settings.",10.1101/2025.10.13.681985,1.0
zinc,zinc,provide,"The work provides experimental evidence for the potential association of zinc over-availability with the occurrence of CAM, and strengthens evidence-based therapeutic practices in clinical settings.",10.1101/2025.10.13.681985,1.0
zinc,zinc,provide,"The work provides experimental evidence for the potential association of zinc over-availability with the occurrence of CAM, and strengthens evidence-based therapeutic practices in clinical settings.",10.1101/2025.10.13.681985,1.0
zinc,zinc,provide,"The work provides experimental evidence for the potential association of zinc over-availability with the occurrence of CAM, and strengthens evidence-based therapeutic practices in clinical settings.",10.1101/2025.10.13.681985,1.0
coronavirus infection,infection,cause,"Here, we report that coronavirus infection causes cytoplasmic poly(A)-binding protein (PABPC) activity to become limiting, which preferentially destabilizes short-tailed host mRNAs, occurring before the action of virally encoded mRNA-decay factor nsp1.",10.1101/2025.10.09.680815,0.5
coronavirus infection,coronavirus infection,cause,"Here, we report that coronavirus infection causes cytoplasmic poly(A)-binding protein (PABPC) activity to become limiting, which preferentially destabilizes short-tailed host mRNAs, occurring before the action of virally encoded mRNA-decay factor nsp1.",10.1101/2025.10.09.680815,1.0
coronavirus infection,infection,cause,"Here, we report that coronavirus infection causes cytoplasmic poly(A)-binding protein (PABPC) activity to become limiting, which preferentially destabilizes short-tailed host mRNAs, occurring before the action of virally encoded mRNA-decay factor nsp1.",10.1101/2025.10.09.680815,0.5
coronavirus infection,infection,promote,"HighlightsO_LIPABPC1 becomes limiting during coronavirus infection C_LIO_LILimiting PABPC1 promotes decay of short-tailed host mRNAs--independently of nsp1 C_LIO_LIThe tail lengths of coronaviral mRNAs are extended during their synthesis in DMVs C_LIO_LIViral tails are capped by PABPC1 and CSDE1, which protects against deadenylation C_LI",10.1101/2025.10.09.680815,0.5
coronavirus infection,coronavirus infection,promote,"HighlightsO_LIPABPC1 becomes limiting during coronavirus infection C_LIO_LILimiting PABPC1 promotes decay of short-tailed host mRNAs--independently of nsp1 C_LIO_LIThe tail lengths of coronaviral mRNAs are extended during their synthesis in DMVs C_LIO_LIViral tails are capped by PABPC1 and CSDE1, which protects against deadenylation C_LI",10.1101/2025.10.09.680815,1.0
coronavirus infection,infection,promote,"HighlightsO_LIPABPC1 becomes limiting during coronavirus infection C_LIO_LILimiting PABPC1 promotes decay of short-tailed host mRNAs--independently of nsp1 C_LIO_LIThe tail lengths of coronaviral mRNAs are extended during their synthesis in DMVs C_LIO_LIViral tails are capped by PABPC1 and CSDE1, which protects against deadenylation C_LI",10.1101/2025.10.09.680815,0.5
upper respiratory tract,infection,represent,"The upper respiratory tract (URT) represents the primary access point for respiratory viruses, where initial host infection occurs.",10.1101/2025.10.09.681417,0.05263157894736842
upper respiratory tract,infection,represent,"The upper respiratory tract (URT) represents the primary access point for respiratory viruses, where initial host infection occurs.",10.1101/2025.10.09.681417,0.05263157894736842
upper respiratory tract,infection,represent,"The upper respiratory tract (URT) represents the primary access point for respiratory viruses, where initial host infection occurs.",10.1101/2025.10.09.681417,0.05263157894736842
infection,infection,occur,"The upper respiratory tract (URT) represents the primary access point for respiratory viruses, where initial host infection occurs.",10.1101/2025.10.09.681417,1.0
infection,infection,occur,"The upper respiratory tract (URT) represents the primary access point for respiratory viruses, where initial host infection occurs.",10.1101/2025.10.09.681417,1.0
infection,infection,occur,"The upper respiratory tract (URT) represents the primary access point for respiratory viruses, where initial host infection occurs.",10.1101/2025.10.09.681417,1.0
infection,infection,control,"Vaccine-mediated URT mucosal memory responses can control infection, prevent transmission and limit viral evolution.",10.1101/2025.10.09.681417,1.0
infection,infection,control,"Vaccine-mediated URT mucosal memory responses can control infection, prevent transmission and limit viral evolution.",10.1101/2025.10.09.681417,1.0
infection,infection,control,"Vaccine-mediated URT mucosal memory responses can control infection, prevent transmission and limit viral evolution.",10.1101/2025.10.09.681417,1.0
infection,infection,block,"However, vaccines against respiratory viruses predominantly have systemic administration routes that elicit strong responses in the circulation to prevent severe respiratory disease, but do not effectively block infection and onward community transmission.",10.1101/2025.10.09.681417,1.0
respiratory disease,infection,elicit,"However, vaccines against respiratory viruses predominantly have systemic administration routes that elicit strong responses in the circulation to prevent severe respiratory disease, but do not effectively block infection and onward community transmission.",10.1101/2025.10.09.681417,0.1111111111111111
infection,infection,block,"However, vaccines against respiratory viruses predominantly have systemic administration routes that elicit strong responses in the circulation to prevent severe respiratory disease, but do not effectively block infection and onward community transmission.",10.1101/2025.10.09.681417,1.0
respiratory disease,infection,elicit,"However, vaccines against respiratory viruses predominantly have systemic administration routes that elicit strong responses in the circulation to prevent severe respiratory disease, but do not effectively block infection and onward community transmission.",10.1101/2025.10.09.681417,0.1111111111111111
infection,infection,block,"However, vaccines against respiratory viruses predominantly have systemic administration routes that elicit strong responses in the circulation to prevent severe respiratory disease, but do not effectively block infection and onward community transmission.",10.1101/2025.10.09.681417,1.0
respiratory disease,infection,elicit,"However, vaccines against respiratory viruses predominantly have systemic administration routes that elicit strong responses in the circulation to prevent severe respiratory disease, but do not effectively block infection and onward community transmission.",10.1101/2025.10.09.681417,0.1111111111111111
methacholine,methacholine,include,"Secondary endpoints were changes in SARS-CoV-2 S1-specific IgG in serum and bronchoalveolar lavage; exploratory endpoints included changes in S1-specific IgA in serum and bronchoalveolar lavage, and methacholine responsiveness.",10.1101/2025.10.07.25337492,1.0
cough,headache,occur,"Over 28 days, mild or moderate adverse events occurred in 87% of participants, predominantly cough, headache, and fatigue, all resolved.",10.1101/2025.10.07.25337492,0.3333333333333333
cough,fatigue,occur,"Over 28 days, mild or moderate adverse events occurred in 87% of participants, predominantly cough, headache, and fatigue, all resolved.",10.1101/2025.10.07.25337492,0.16666666666666666
headache,fatigue,occur,"Over 28 days, mild or moderate adverse events occurred in 87% of participants, predominantly cough, headache, and fatigue, all resolved.",10.1101/2025.10.07.25337492,0.25
methacholine,methacholine,normalize,"Pulmonary function and methacholine responsiveness were stable, except for one transient 20% decrease in FEV1 on Day 14 that normalized subsequently.",10.1101/2025.10.07.25337492,1.0
HPV-associated cancer,cancer,focus,"Focusing on Iowa, a state with the fastest rising incidence of HPV-associated cancer, we evaluated if county-level COVID-19 vaccination rates corresponded to county-level changes in rural-urban HPV vaccination completion trends.",10.1101/2025.10.07.25337497,0.5
PK,PD,evaluate,"Participants were monitored for 43 weeks to evaluate safety, pharmacokinetics (PK), and pharmacodynamics (PD; serum live virus neutralization).",10.1101/2025.10.07.25337449,0.14285714285714285
Respiratory Syndrome,coronavirus disease 2019,target,Ensitrelvir is an antiviral drug that specifically targets the main protease (Mpro) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has been approved for the treatment of coronavirus disease 2019 (COVID-19) due to the conservation of its target protein which is essential in the viral lifecycle.,10.1101/2025.09.30.679586,0.06666666666666667
{Delta}3a7b-Nluc,{Delta}3a7b-Nluc,utilize,"Here, we utilized a luminescent attenuated SARS-CoV-2 ({Delta}3a7b-Nluc WT) to safely identify ensitrelvir drug-resistant mutants (DRM-E) without the need of using virulent forms of SARS-CoV-2.",10.1101/2025.09.30.679586,1.0
{Delta}3a7b-Nluc,{Delta}3a7b-Nluc,contain,The contribution of G23del was confirmed by generating a recombinant luminescent attenuated SARS-CoV-2 containing G23del in the non-structural protein 5 (NSP5) gene ({Delta}3a7b-Nluc G23del).,10.1101/2025.09.30.679586,1.0
{Delta}3a7b-Nluc,{Delta}3a7b-Nluc,exhibit,{Delta}3a7b-Nluc G23del exhibited significant resistance to ensitrelvir in both cultured cells an in K18 hACE2 transgenic mice.,10.1101/2025.09.30.679586,1.0
"nirmatrelvir or remdesivir, suggesting the feasibility of treating",infections,render,"Positively, G23del in Mpro does not render SARS-CoV-2 resistant to nirmatrelvir or remdesivir, suggesting the feasibility of treating infections with SARS-CoV-2 containing G23del with these other approved antivirals.",10.1101/2025.09.30.679586,0.1
{Delta}3a7b-Nluc,{Delta}3a7b-Nluc,employ,Our study addresses this by employing a luminescent attenuated virus platform ({Delta}3a7b-Nluc WT) to safely identify and characterize resistance mutations without the concern of using virulent forms of SARS-CoV-2.,10.1101/2025.09.30.679586,1.0
{Delta}3a7b-Nluc,{Delta}3a7b-Nluc,use,"Altogether, this study demonstrates the feasibility of using {Delta}3a7b-Nluc to safely identify and characterize drug resistant viruses without the biosafety concern of using virulent SARS-CoV-2 and advance the design of next-generation antiviral drugs.",10.1101/2025.09.30.679586,1.0
LTLAs,LTLAs,stratify,MethodsWe performed a DTW analysis on COVID-19 case time series stratified by the 380 Lower Tier Local Authorities (LTLAs) in the UK.,10.1101/2025.10.05.25337392,1.0
LTLAs,LTLAs,stratify,MethodsWe performed a DTW analysis on COVID-19 case time series stratified by the 380 Lower Tier Local Authorities (LTLAs) in the UK.,10.1101/2025.10.05.25337392,1.0
LTLAs,LTLAs,stratify,MethodsWe performed a DTW analysis on COVID-19 case time series stratified by the 380 Lower Tier Local Authorities (LTLAs) in the UK.,10.1101/2025.10.05.25337392,1.0
LTLAs,LTLAs,stratify,MethodsWe performed a DTW analysis on COVID-19 case time series stratified by the 380 Lower Tier Local Authorities (LTLAs) in the UK.,10.1101/2025.10.05.25337392,1.0
LTLAs,LTLAs,stratify,MethodsWe performed a DTW analysis on COVID-19 case time series stratified by the 380 Lower Tier Local Authorities (LTLAs) in the UK.,10.1101/2025.10.05.25337392,1.0
LTLAs,LTLAs,stratify,MethodsWe performed a DTW analysis on COVID-19 case time series stratified by the 380 Lower Tier Local Authorities (LTLAs) in the UK.,10.1101/2025.10.05.25337392,1.0
LTLAs,LTLAs,find,"ResultsOur clustering analysis found that case time series for LTLAs of Wales, Scotland, Northern Ireland and England were closely related to LTLAs within the same nation.",10.1101/2025.10.05.25337392,1.0
LTLAs,LTLAs,find,"ResultsOur clustering analysis found that case time series for LTLAs of Wales, Scotland, Northern Ireland and England were closely related to LTLAs within the same nation.",10.1101/2025.10.05.25337392,1.0
LTLAs,LTLAs,find,"ResultsOur clustering analysis found that case time series for LTLAs of Wales, Scotland, Northern Ireland and England were closely related to LTLAs within the same nation.",10.1101/2025.10.05.25337392,1.0
LTLAs,LTLAs,find,"ResultsOur clustering analysis found that case time series for LTLAs of Wales, Scotland, Northern Ireland and England were closely related to LTLAs within the same nation.",10.1101/2025.10.05.25337392,1.0
LTLAs,LTLAs,find,"ResultsOur clustering analysis found that case time series for LTLAs of Wales, Scotland, Northern Ireland and England were closely related to LTLAs within the same nation.",10.1101/2025.10.05.25337392,1.0
LTLAs,LTLAs,find,"ResultsOur clustering analysis found that case time series for LTLAs of Wales, Scotland, Northern Ireland and England were closely related to LTLAs within the same nation.",10.1101/2025.10.05.25337392,1.0
LTLAs,LTLAs,identify,We identified groups of LTLAs in England with highly similar trends in case time series; these groups of LTLAs were geographically clustered despite the methodology not using any geographic information as input.,10.1101/2025.10.05.25337392,1.0
LTLAs,LTLAs,identify,We identified groups of LTLAs in England with highly similar trends in case time series; these groups of LTLAs were geographically clustered despite the methodology not using any geographic information as input.,10.1101/2025.10.05.25337392,1.0
LTLAs,LTLAs,identify,We identified groups of LTLAs in England with highly similar trends in case time series; these groups of LTLAs were geographically clustered despite the methodology not using any geographic information as input.,10.1101/2025.10.05.25337392,1.0
LTLAs,LTLAs,identify,We identified groups of LTLAs in England with highly similar trends in case time series; these groups of LTLAs were geographically clustered despite the methodology not using any geographic information as input.,10.1101/2025.10.05.25337392,1.0
LTLAs,LTLAs,identify,We identified groups of LTLAs in England with highly similar trends in case time series; these groups of LTLAs were geographically clustered despite the methodology not using any geographic information as input.,10.1101/2025.10.05.25337392,1.0
LTLAs,LTLAs,identify,We identified groups of LTLAs in England with highly similar trends in case time series; these groups of LTLAs were geographically clustered despite the methodology not using any geographic information as input.,10.1101/2025.10.05.25337392,1.0
LTLAs,LTLAs,lead,"The lead-lag time analysis in England showed that LTLAs in southeast England, the Manchester area, and in London each led the Alpha, Delta, and Omicron BA.1 epidemic waves respectively.",10.1101/2025.10.05.25337392,1.0
LTLAs,LTLAs,lead,"The lead-lag time analysis in England showed that LTLAs in southeast England, the Manchester area, and in London each led the Alpha, Delta, and Omicron BA.1 epidemic waves respectively.",10.1101/2025.10.05.25337392,1.0
LTLAs,LTLAs,lead,"The lead-lag time analysis in England showed that LTLAs in southeast England, the Manchester area, and in London each led the Alpha, Delta, and Omicron BA.1 epidemic waves respectively.",10.1101/2025.10.05.25337392,1.0
LTLAs,LTLAs,lead,"The lead-lag time analysis in England showed that LTLAs in southeast England, the Manchester area, and in London each led the Alpha, Delta, and Omicron BA.1 epidemic waves respectively.",10.1101/2025.10.05.25337392,1.0
LTLAs,LTLAs,lead,"The lead-lag time analysis in England showed that LTLAs in southeast England, the Manchester area, and in London each led the Alpha, Delta, and Omicron BA.1 epidemic waves respectively.",10.1101/2025.10.05.25337392,1.0
LTLAs,LTLAs,lead,"The lead-lag time analysis in England showed that LTLAs in southeast England, the Manchester area, and in London each led the Alpha, Delta, and Omicron BA.1 epidemic waves respectively.",10.1101/2025.10.05.25337392,1.0
nontuberculous mycobacterial,NTM,increase,"BackgroundThe incidence of nontuberculous mycobacterial (NTM) diseases is increasing globally, with risk factors remaining poorly understood.",10.1101/2025.10.02.25337223,0.25
nontuberculous mycobacterial,NTM,increase,"BackgroundThe incidence of nontuberculous mycobacterial (NTM) diseases is increasing globally, with risk factors remaining poorly understood.",10.1101/2025.10.02.25337223,0.25
nontuberculous mycobacterial,NTM,increase,"BackgroundThe incidence of nontuberculous mycobacterial (NTM) diseases is increasing globally, with risk factors remaining poorly understood.",10.1101/2025.10.02.25337223,0.25
NTM,NTM,increase,"BackgroundThe incidence of nontuberculous mycobacterial (NTM) diseases is increasing globally, with risk factors remaining poorly understood.",10.1101/2025.10.02.25337223,1.0
NTM,NTM,increase,"BackgroundThe incidence of nontuberculous mycobacterial (NTM) diseases is increasing globally, with risk factors remaining poorly understood.",10.1101/2025.10.02.25337223,1.0
NTM,NTM,increase,"BackgroundThe incidence of nontuberculous mycobacterial (NTM) diseases is increasing globally, with risk factors remaining poorly understood.",10.1101/2025.10.02.25337223,1.0
NTM,NTM,affect,COVID-19 may alter respiratory tract conditions affecting NTM colonization and infection patterns.,10.1101/2025.10.02.25337223,1.0
NTM,infection,affect,COVID-19 may alter respiratory tract conditions affecting NTM colonization and infection patterns.,10.1101/2025.10.02.25337223,0.25
NTM,NTM,affect,COVID-19 may alter respiratory tract conditions affecting NTM colonization and infection patterns.,10.1101/2025.10.02.25337223,1.0
NTM,infection,affect,COVID-19 may alter respiratory tract conditions affecting NTM colonization and infection patterns.,10.1101/2025.10.02.25337223,0.25
NTM,NTM,affect,COVID-19 may alter respiratory tract conditions affecting NTM colonization and infection patterns.,10.1101/2025.10.02.25337223,1.0
NTM,infection,affect,COVID-19 may alter respiratory tract conditions affecting NTM colonization and infection patterns.,10.1101/2025.10.02.25337223,0.25
NTM,NTM,evaluate,ObjectiveTo evaluate species diversity of NTM isolated from patients with NTM-associated diseases with and without a history of COVID-19.,10.1101/2025.10.02.25337223,1.0
NTM,NTM,evaluate,ObjectiveTo evaluate species diversity of NTM isolated from patients with NTM-associated diseases with and without a history of COVID-19.,10.1101/2025.10.02.25337223,1.0
NTM,NTM-associated diseases,evaluate,ObjectiveTo evaluate species diversity of NTM isolated from patients with NTM-associated diseases with and without a history of COVID-19.,10.1101/2025.10.02.25337223,0.16666666666666666
NTM,NTM-associated diseases,evaluate,ObjectiveTo evaluate species diversity of NTM isolated from patients with NTM-associated diseases with and without a history of COVID-19.,10.1101/2025.10.02.25337223,0.16666666666666666
NTM,NTM,evaluate,ObjectiveTo evaluate species diversity of NTM isolated from patients with NTM-associated diseases with and without a history of COVID-19.,10.1101/2025.10.02.25337223,1.0
NTM,NTM-associated diseases,evaluate,ObjectiveTo evaluate species diversity of NTM isolated from patients with NTM-associated diseases with and without a history of COVID-19.,10.1101/2025.10.02.25337223,0.16666666666666666
NTM,NTM-associated diseases,evaluate,ObjectiveTo evaluate species diversity of NTM isolated from patients with NTM-associated diseases with and without a history of COVID-19.,10.1101/2025.10.02.25337223,0.16666666666666666
NTM,NTM-associated diseases,evaluate,ObjectiveTo evaluate species diversity of NTM isolated from patients with NTM-associated diseases with and without a history of COVID-19.,10.1101/2025.10.02.25337223,0.16666666666666666
NTM,NTM-associated diseases,evaluate,ObjectiveTo evaluate species diversity of NTM isolated from patients with NTM-associated diseases with and without a history of COVID-19.,10.1101/2025.10.02.25337223,0.16666666666666666
NTM-associated diseases,NTM-associated diseases,isolate,ObjectiveTo evaluate species diversity of NTM isolated from patients with NTM-associated diseases with and without a history of COVID-19.,10.1101/2025.10.02.25337223,1.0
NTM,NTM,analyze,"MethodsWe analyzed 464 clinical NTM isolates from Russian patients stratified by COVID-19 status (COVID-19+, n=271; COVID-19-, n=193).",10.1101/2025.10.02.25337223,1.0
NTM,NTM,analyze,"MethodsWe analyzed 464 clinical NTM isolates from Russian patients stratified by COVID-19 status (COVID-19+, n=271; COVID-19-, n=193).",10.1101/2025.10.02.25337223,1.0
NTM,NTM,analyze,"MethodsWe analyzed 464 clinical NTM isolates from Russian patients stratified by COVID-19 status (COVID-19+, n=271; COVID-19-, n=193).",10.1101/2025.10.02.25337223,1.0
Mycobacterium avium,avium,associate,"COVID-19 was associated with a significant 28% reduction in Mycobacterium avium complex (MAC) prevalence (94.8% vs 66.8%, p<0.05), primarily due to decreased M. avium isolation (80.3% vs 52.0%, p<0.05).",10.1101/2025.10.02.25337223,0.5
NTM,NTM,show,"Conversely, rare NTM species showed increased prevalence in COVID-19+ patients: M. kansasii complex (0% vs 8.1%, p<0.05), M. terrae complex (0% vs 3.3%, p<0.05), M. simiae complex (0.5% vs 7.0%, p<0.05), and unclassifiable species (2.6% vs 12.9%, p<0.05).",10.1101/2025.10.02.25337223,1.0
NTM,NTM,show,"Conversely, rare NTM species showed increased prevalence in COVID-19+ patients: M. kansasii complex (0% vs 8.1%, p<0.05), M. terrae complex (0% vs 3.3%, p<0.05), M. simiae complex (0.5% vs 7.0%, p<0.05), and unclassifiable species (2.6% vs 12.9%, p<0.05).",10.1101/2025.10.02.25337223,1.0
NTM,terrae,show,"Conversely, rare NTM species showed increased prevalence in COVID-19+ patients: M. kansasii complex (0% vs 8.1%, p<0.05), M. terrae complex (0% vs 3.3%, p<0.05), M. simiae complex (0.5% vs 7.0%, p<0.05), and unclassifiable species (2.6% vs 12.9%, p<0.05).",10.1101/2025.10.02.25337223,0.04
NTM,NTM,show,"Conversely, rare NTM species showed increased prevalence in COVID-19+ patients: M. kansasii complex (0% vs 8.1%, p<0.05), M. terrae complex (0% vs 3.3%, p<0.05), M. simiae complex (0.5% vs 7.0%, p<0.05), and unclassifiable species (2.6% vs 12.9%, p<0.05).",10.1101/2025.10.02.25337223,1.0
NTM,terrae,show,"Conversely, rare NTM species showed increased prevalence in COVID-19+ patients: M. kansasii complex (0% vs 8.1%, p<0.05), M. terrae complex (0% vs 3.3%, p<0.05), M. simiae complex (0.5% vs 7.0%, p<0.05), and unclassifiable species (2.6% vs 12.9%, p<0.05).",10.1101/2025.10.02.25337223,0.04
NTM,terrae,show,"Conversely, rare NTM species showed increased prevalence in COVID-19+ patients: M. kansasii complex (0% vs 8.1%, p<0.05), M. terrae complex (0% vs 3.3%, p<0.05), M. simiae complex (0.5% vs 7.0%, p<0.05), and unclassifiable species (2.6% vs 12.9%, p<0.05).",10.1101/2025.10.02.25337223,0.04
NTM,NTM,alter,"ConclusionsCOVID-19 significantly alters the NTM species spectrum in patients with NTM-associated diseases, with reduced MAC prevalence and increased detection of rare NTM species.",10.1101/2025.10.02.25337223,1.0
NTM,NTM,alter,"ConclusionsCOVID-19 significantly alters the NTM species spectrum in patients with NTM-associated diseases, with reduced MAC prevalence and increased detection of rare NTM species.",10.1101/2025.10.02.25337223,1.0
NTM,NTM-associated diseases,alter,"ConclusionsCOVID-19 significantly alters the NTM species spectrum in patients with NTM-associated diseases, with reduced MAC prevalence and increased detection of rare NTM species.",10.1101/2025.10.02.25337223,0.14285714285714285
NTM,NTM-associated diseases,alter,"ConclusionsCOVID-19 significantly alters the NTM species spectrum in patients with NTM-associated diseases, with reduced MAC prevalence and increased detection of rare NTM species.",10.1101/2025.10.02.25337223,0.14285714285714285
NTM,NTM,alter,"ConclusionsCOVID-19 significantly alters the NTM species spectrum in patients with NTM-associated diseases, with reduced MAC prevalence and increased detection of rare NTM species.",10.1101/2025.10.02.25337223,1.0
NTM,NTM-associated diseases,alter,"ConclusionsCOVID-19 significantly alters the NTM species spectrum in patients with NTM-associated diseases, with reduced MAC prevalence and increased detection of rare NTM species.",10.1101/2025.10.02.25337223,0.14285714285714285
NTM,NTM-associated diseases,alter,"ConclusionsCOVID-19 significantly alters the NTM species spectrum in patients with NTM-associated diseases, with reduced MAC prevalence and increased detection of rare NTM species.",10.1101/2025.10.02.25337223,0.14285714285714285
NTM,NTM-associated diseases,alter,"ConclusionsCOVID-19 significantly alters the NTM species spectrum in patients with NTM-associated diseases, with reduced MAC prevalence and increased detection of rare NTM species.",10.1101/2025.10.02.25337223,0.14285714285714285
NTM,NTM-associated diseases,alter,"ConclusionsCOVID-19 significantly alters the NTM species spectrum in patients with NTM-associated diseases, with reduced MAC prevalence and increased detection of rare NTM species.",10.1101/2025.10.02.25337223,0.14285714285714285
NTM-associated diseases,NTM-associated diseases,alter,"ConclusionsCOVID-19 significantly alters the NTM species spectrum in patients with NTM-associated diseases, with reduced MAC prevalence and increased detection of rare NTM species.",10.1101/2025.10.02.25337223,1.0
infection,infection,limit,"The ease with which emerging SARS-CoV-2 variants escape neutralizing antibodies limits protection afforded by a prior exposure, be it infection or vaccination.",10.1101/2025.10.03.679858,1.0
infection,infection,compare,"Motivated by findings that plasma responses show increased neutralization breadth and potency with continued antigen exposure, we isolated monoclonal antibodies (mAbs) after a SARS-CoV-2 re-infection and compared them to those isolated one year prior, after the first breakthrough infection.",10.1101/2025.10.03.679858,1.0
SARS,SARS,record,The target population were all the reported and recorded SARS CoV-2 cases above 15 years and all active cases.,10.1101/2025.09.27.25336412,1.0
SARS,SARS,have,Results624 participated in this study with 528 cases having had tested or confirmed records of SARS CoV-2 test status with mean age 32 (SD10.3).,10.1101/2025.09.27.25336412,1.0
infection,infection,observe,"Persons observed at risk of severe cases of infection were; elderly males above 49 years (cOR=2.13, 95% CI: 1.16-3.89, p<0.014), and those who had other co-morbidities (43%).",10.1101/2025.09.27.25336412,1.0
SARS,SARS,unknown,"ConclusionMajority of the population were knowledgeable about the causes, transmission risks and the SARS CoV-2 prevention guidelines.",10.1101/2025.09.27.25336412,1.0
SARS,SARS,adhere,Failure to adhere to the stipulated SARS CoV-2 prevention guidelines accounted for most of the increases transmission rate among the sub-populations.,10.1101/2025.09.27.25336412,1.0
infection,infection,affect,Adults above 49 years with other co-commodities and not vaccinated were the most affected with the infection,10.1101/2025.09.27.25336412,1.0
TACO,TACO,present,"We present TACO (TabPFN Augmented Causal Outcomes), a framework that uniquely combines causal inference with foundation models for presymptomatic Long COVID detection.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,present,"We present TACO (TabPFN Augmented Causal Outcomes), a framework that uniquely combines causal inference with foundation models for presymptomatic Long COVID detection.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,present,"We present TACO (TabPFN Augmented Causal Outcomes), a framework that uniquely combines causal inference with foundation models for presymptomatic Long COVID detection.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,present,"We present TACO (TabPFN Augmented Causal Outcomes), a framework that uniquely combines causal inference with foundation models for presymptomatic Long COVID detection.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,present,"We present TACO (TabPFN Augmented Causal Outcomes), a framework that uniquely combines causal inference with foundation models for presymptomatic Long COVID detection.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,present,"We present TACO (TabPFN Augmented Causal Outcomes), a framework that uniquely combines causal inference with foundation models for presymptomatic Long COVID detection.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,present,"We present TACO (TabPFN Augmented Causal Outcomes), a framework that uniquely combines causal inference with foundation models for presymptomatic Long COVID detection.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,present,"We present TACO (TabPFN Augmented Causal Outcomes), a framework that uniquely combines causal inference with foundation models for presymptomatic Long COVID detection.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,present,"We present TACO (TabPFN Augmented Causal Outcomes), a framework that uniquely combines causal inference with foundation models for presymptomatic Long COVID detection.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,present,"We present TACO (TabPFN Augmented Causal Outcomes), a framework that uniquely combines causal inference with foundation models for presymptomatic Long COVID detection.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,employ,"TACO employs Differential Causal Effect (DCE) analysis to identify causally relevant genes, then utilizes TabPFN, a foundation model that does not require hyperparameter adjustment, to achieve consistent performance.",10.1101/2025.10.02.25337138,1.0
TACO,DCE,employ,"TACO employs Differential Causal Effect (DCE) analysis to identify causally relevant genes, then utilizes TabPFN, a foundation model that does not require hyperparameter adjustment, to achieve consistent performance.",10.1101/2025.10.02.25337138,0.14285714285714285
TACO,TACO,employ,"TACO employs Differential Causal Effect (DCE) analysis to identify causally relevant genes, then utilizes TabPFN, a foundation model that does not require hyperparameter adjustment, to achieve consistent performance.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,employ,"TACO employs Differential Causal Effect (DCE) analysis to identify causally relevant genes, then utilizes TabPFN, a foundation model that does not require hyperparameter adjustment, to achieve consistent performance.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,employ,"TACO employs Differential Causal Effect (DCE) analysis to identify causally relevant genes, then utilizes TabPFN, a foundation model that does not require hyperparameter adjustment, to achieve consistent performance.",10.1101/2025.10.02.25337138,1.0
TACO,DCE,employ,"TACO employs Differential Causal Effect (DCE) analysis to identify causally relevant genes, then utilizes TabPFN, a foundation model that does not require hyperparameter adjustment, to achieve consistent performance.",10.1101/2025.10.02.25337138,0.14285714285714285
TACO,TACO,employ,"TACO employs Differential Causal Effect (DCE) analysis to identify causally relevant genes, then utilizes TabPFN, a foundation model that does not require hyperparameter adjustment, to achieve consistent performance.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,employ,"TACO employs Differential Causal Effect (DCE) analysis to identify causally relevant genes, then utilizes TabPFN, a foundation model that does not require hyperparameter adjustment, to achieve consistent performance.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,employ,"TACO employs Differential Causal Effect (DCE) analysis to identify causally relevant genes, then utilizes TabPFN, a foundation model that does not require hyperparameter adjustment, to achieve consistent performance.",10.1101/2025.10.02.25337138,1.0
TACO,DCE,employ,"TACO employs Differential Causal Effect (DCE) analysis to identify causally relevant genes, then utilizes TabPFN, a foundation model that does not require hyperparameter adjustment, to achieve consistent performance.",10.1101/2025.10.02.25337138,0.14285714285714285
TACO,DCE,employ,"TACO employs Differential Causal Effect (DCE) analysis to identify causally relevant genes, then utilizes TabPFN, a foundation model that does not require hyperparameter adjustment, to achieve consistent performance.",10.1101/2025.10.02.25337138,0.14285714285714285
TACO,DCE,employ,"TACO employs Differential Causal Effect (DCE) analysis to identify causally relevant genes, then utilizes TabPFN, a foundation model that does not require hyperparameter adjustment, to achieve consistent performance.",10.1101/2025.10.02.25337138,0.14285714285714285
TACO,TACO,employ,"TACO employs Differential Causal Effect (DCE) analysis to identify causally relevant genes, then utilizes TabPFN, a foundation model that does not require hyperparameter adjustment, to achieve consistent performance.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,employ,"TACO employs Differential Causal Effect (DCE) analysis to identify causally relevant genes, then utilizes TabPFN, a foundation model that does not require hyperparameter adjustment, to achieve consistent performance.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,employ,"TACO employs Differential Causal Effect (DCE) analysis to identify causally relevant genes, then utilizes TabPFN, a foundation model that does not require hyperparameter adjustment, to achieve consistent performance.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,achieve,"In comprehensive benchmarking, TACO achieved superior precision using 18% fewer features than conventional approaches.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,achieve,"In comprehensive benchmarking, TACO achieved superior precision using 18% fewer features than conventional approaches.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,achieve,"In comprehensive benchmarking, TACO achieved superior precision using 18% fewer features than conventional approaches.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,achieve,"In comprehensive benchmarking, TACO achieved superior precision using 18% fewer features than conventional approaches.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,achieve,"In comprehensive benchmarking, TACO achieved superior precision using 18% fewer features than conventional approaches.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,achieve,"In comprehensive benchmarking, TACO achieved superior precision using 18% fewer features than conventional approaches.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,achieve,"In comprehensive benchmarking, TACO achieved superior precision using 18% fewer features than conventional approaches.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,achieve,"In comprehensive benchmarking, TACO achieved superior precision using 18% fewer features than conventional approaches.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,achieve,"In comprehensive benchmarking, TACO achieved superior precision using 18% fewer features than conventional approaches.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,achieve,"In comprehensive benchmarking, TACO achieved superior precision using 18% fewer features than conventional approaches.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,maintain,"Critically, TACO maintains consistent performance without any hyperparameter optimization, while benchmark models show variable results depending on the tuning.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,maintain,"Critically, TACO maintains consistent performance without any hyperparameter optimization, while benchmark models show variable results depending on the tuning.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,maintain,"Critically, TACO maintains consistent performance without any hyperparameter optimization, while benchmark models show variable results depending on the tuning.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,maintain,"Critically, TACO maintains consistent performance without any hyperparameter optimization, while benchmark models show variable results depending on the tuning.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,maintain,"Critically, TACO maintains consistent performance without any hyperparameter optimization, while benchmark models show variable results depending on the tuning.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,maintain,"Critically, TACO maintains consistent performance without any hyperparameter optimization, while benchmark models show variable results depending on the tuning.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,maintain,"Critically, TACO maintains consistent performance without any hyperparameter optimization, while benchmark models show variable results depending on the tuning.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,maintain,"Critically, TACO maintains consistent performance without any hyperparameter optimization, while benchmark models show variable results depending on the tuning.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,maintain,"Critically, TACO maintains consistent performance without any hyperparameter optimization, while benchmark models show variable results depending on the tuning.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,maintain,"Critically, TACO maintains consistent performance without any hyperparameter optimization, while benchmark models show variable results depending on the tuning.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,offer,"By prioritizing causal mechanisms over statistical associations and eliminating the need for hyperparameter search, TACO offers a practical, interpretable solution for clinical deployment, transforming Long COVID management from reactive diagnosis to proactive prevention.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,offer,"By prioritizing causal mechanisms over statistical associations and eliminating the need for hyperparameter search, TACO offers a practical, interpretable solution for clinical deployment, transforming Long COVID management from reactive diagnosis to proactive prevention.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,offer,"By prioritizing causal mechanisms over statistical associations and eliminating the need for hyperparameter search, TACO offers a practical, interpretable solution for clinical deployment, transforming Long COVID management from reactive diagnosis to proactive prevention.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,offer,"By prioritizing causal mechanisms over statistical associations and eliminating the need for hyperparameter search, TACO offers a practical, interpretable solution for clinical deployment, transforming Long COVID management from reactive diagnosis to proactive prevention.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,offer,"By prioritizing causal mechanisms over statistical associations and eliminating the need for hyperparameter search, TACO offers a practical, interpretable solution for clinical deployment, transforming Long COVID management from reactive diagnosis to proactive prevention.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,offer,"By prioritizing causal mechanisms over statistical associations and eliminating the need for hyperparameter search, TACO offers a practical, interpretable solution for clinical deployment, transforming Long COVID management from reactive diagnosis to proactive prevention.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,offer,"By prioritizing causal mechanisms over statistical associations and eliminating the need for hyperparameter search, TACO offers a practical, interpretable solution for clinical deployment, transforming Long COVID management from reactive diagnosis to proactive prevention.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,offer,"By prioritizing causal mechanisms over statistical associations and eliminating the need for hyperparameter search, TACO offers a practical, interpretable solution for clinical deployment, transforming Long COVID management from reactive diagnosis to proactive prevention.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,offer,"By prioritizing causal mechanisms over statistical associations and eliminating the need for hyperparameter search, TACO offers a practical, interpretable solution for clinical deployment, transforming Long COVID management from reactive diagnosis to proactive prevention.",10.1101/2025.10.02.25337138,1.0
TACO,TACO,offer,"By prioritizing causal mechanisms over statistical associations and eliminating the need for hyperparameter search, TACO offers a practical, interpretable solution for clinical deployment, transforming Long COVID management from reactive diagnosis to proactive prevention.",10.1101/2025.10.02.25337138,1.0
sHCoVs,OC43,impact,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743,0.2
OC43,OC43,impact,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,impact,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,impact,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,impact,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,impact,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,impact,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743,1.0
sHCoVs,OC43,impact,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743,0.2
sHCoVs,OC43,impact,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743,0.2
sHCoVs,OC43,impact,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743,0.2
sHCoVs,OC43,impact,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743,0.2
sHCoVs,OC43,impact,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743,0.2
sHCoVs,OC43,impact,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743,0.2
OC43,OC43,impact,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,impact,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,impact,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,impact,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,impact,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,impact,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,impact,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,impact,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,impact,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,impact,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,impact,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,impact,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,impact,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,impact,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,impact,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,determine,"Subsequently, we determined the OC43 neutralization potential of sera and monoclonal antibodies targeting different S domains.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,determine,"Subsequently, we determined the OC43 neutralization potential of sera and monoclonal antibodies targeting different S domains.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,determine,"Subsequently, we determined the OC43 neutralization potential of sera and monoclonal antibodies targeting different S domains.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,determine,"Subsequently, we determined the OC43 neutralization potential of sera and monoclonal antibodies targeting different S domains.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,determine,"Subsequently, we determined the OC43 neutralization potential of sera and monoclonal antibodies targeting different S domains.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,determine,"Subsequently, we determined the OC43 neutralization potential of sera and monoclonal antibodies targeting different S domains.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,determine,"Subsequently, we determined the OC43 neutralization potential of sera and monoclonal antibodies targeting different S domains.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,determine,"Subsequently, we determined the OC43 neutralization potential of sera and monoclonal antibodies targeting different S domains.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,determine,"Subsequently, we determined the OC43 neutralization potential of sera and monoclonal antibodies targeting different S domains.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,determine,"Subsequently, we determined the OC43 neutralization potential of sera and monoclonal antibodies targeting different S domains.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,determine,"Subsequently, we determined the OC43 neutralization potential of sera and monoclonal antibodies targeting different S domains.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,determine,"Subsequently, we determined the OC43 neutralization potential of sera and monoclonal antibodies targeting different S domains.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,determine,"Subsequently, we determined the OC43 neutralization potential of sera and monoclonal antibodies targeting different S domains.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,determine,"Subsequently, we determined the OC43 neutralization potential of sera and monoclonal antibodies targeting different S domains.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,determine,"Subsequently, we determined the OC43 neutralization potential of sera and monoclonal antibodies targeting different S domains.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,determine,"Subsequently, we determined the OC43 neutralization potential of sera and monoclonal antibodies targeting different S domains.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,determine,"Subsequently, we determined the OC43 neutralization potential of sera and monoclonal antibodies targeting different S domains.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,determine,"Subsequently, we determined the OC43 neutralization potential of sera and monoclonal antibodies targeting different S domains.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,determine,"Subsequently, we determined the OC43 neutralization potential of sera and monoclonal antibodies targeting different S domains.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,determine,"Subsequently, we determined the OC43 neutralization potential of sera and monoclonal antibodies targeting different S domains.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,determine,"Subsequently, we determined the OC43 neutralization potential of sera and monoclonal antibodies targeting different S domains.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,account,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743,1.0
NL63,OC43,account,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743,0.25
OC43,OC43,account,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743,1.0
OC43,OC43,account,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743,1.0
OC43,OC43,account,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743,1.0
OC43,OC43,account,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743,1.0
OC43,OC43,account,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743,1.0
NL63,OC43,account,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743,0.25
NL63,OC43,account,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743,0.25
OC43,OC43,account,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743,1.0
OC43,OC43,account,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743,1.0
OC43,OC43,account,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743,1.0
OC43,OC43,account,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743,1.0
OC43,OC43,account,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743,1.0
NL63,OC43,account,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743,0.25
NL63,OC43,account,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743,0.25
NL63,OC43,account,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743,0.25
NL63,OC43,account,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743,0.25
NL63,OC43,account,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743,0.25
NL63,OC43,account,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743,0.25
NL63,NL63,account,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743,1.0
OC43,OC43,account,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743,1.0
OC43,OC43,account,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743,1.0
OC43,OC43,account,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743,1.0
OC43,OC43,account,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743,1.0
NL63,OC43,account,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743,0.25
OC43,OC43,account,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743,1.0
OC43,OC43,account,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743,1.0
OC43,OC43,account,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743,1.0
NL63,OC43,account,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743,0.25
OC43,OC43,account,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743,1.0
OC43,OC43,account,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743,1.0
NL63,OC43,account,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743,0.25
OC43,OC43,account,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743,1.0
NL63,OC43,account,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743,0.25
NL63,OC43,account,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743,0.25
OC43,OC43,result,"For OC43, the immunodominance of SARS-CoV-2/OC43 cross-reactive IgG B-cells resulted in a strong bias towards S2.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,result,"For OC43, the immunodominance of SARS-CoV-2/OC43 cross-reactive IgG B-cells resulted in a strong bias towards S2.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,result,"For OC43, the immunodominance of SARS-CoV-2/OC43 cross-reactive IgG B-cells resulted in a strong bias towards S2.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,result,"For OC43, the immunodominance of SARS-CoV-2/OC43 cross-reactive IgG B-cells resulted in a strong bias towards S2.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,result,"For OC43, the immunodominance of SARS-CoV-2/OC43 cross-reactive IgG B-cells resulted in a strong bias towards S2.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,result,"For OC43, the immunodominance of SARS-CoV-2/OC43 cross-reactive IgG B-cells resulted in a strong bias towards S2.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,result,"For OC43, the immunodominance of SARS-CoV-2/OC43 cross-reactive IgG B-cells resulted in a strong bias towards S2.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,result,"For OC43, the immunodominance of SARS-CoV-2/OC43 cross-reactive IgG B-cells resulted in a strong bias towards S2.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,result,"For OC43, the immunodominance of SARS-CoV-2/OC43 cross-reactive IgG B-cells resulted in a strong bias towards S2.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,result,"For OC43, the immunodominance of SARS-CoV-2/OC43 cross-reactive IgG B-cells resulted in a strong bias towards S2.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,result,"For OC43, the immunodominance of SARS-CoV-2/OC43 cross-reactive IgG B-cells resulted in a strong bias towards S2.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,result,"For OC43, the immunodominance of SARS-CoV-2/OC43 cross-reactive IgG B-cells resulted in a strong bias towards S2.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,result,"For OC43, the immunodominance of SARS-CoV-2/OC43 cross-reactive IgG B-cells resulted in a strong bias towards S2.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,result,"For OC43, the immunodominance of SARS-CoV-2/OC43 cross-reactive IgG B-cells resulted in a strong bias towards S2.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,result,"For OC43, the immunodominance of SARS-CoV-2/OC43 cross-reactive IgG B-cells resulted in a strong bias towards S2.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,result,"For OC43, the immunodominance of SARS-CoV-2/OC43 cross-reactive IgG B-cells resulted in a strong bias towards S2.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,result,"For OC43, the immunodominance of SARS-CoV-2/OC43 cross-reactive IgG B-cells resulted in a strong bias towards S2.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,result,"For OC43, the immunodominance of SARS-CoV-2/OC43 cross-reactive IgG B-cells resulted in a strong bias towards S2.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,result,"For OC43, the immunodominance of SARS-CoV-2/OC43 cross-reactive IgG B-cells resulted in a strong bias towards S2.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,result,"For OC43, the immunodominance of SARS-CoV-2/OC43 cross-reactive IgG B-cells resulted in a strong bias towards S2.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,result,"For OC43, the immunodominance of SARS-CoV-2/OC43 cross-reactive IgG B-cells resulted in a strong bias towards S2.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,correlate,Serum OC43 neutralization titers were higher in end-pandemic donors and correlated with OC43 S1 and S2-specific IgG titers and reactive B-cells frequencies.,10.1101/2025.09.28.25336743,1.0
OC43,OC43,correlate,Serum OC43 neutralization titers were higher in end-pandemic donors and correlated with OC43 S1 and S2-specific IgG titers and reactive B-cells frequencies.,10.1101/2025.09.28.25336743,1.0
OC43,OC43,correlate,Serum OC43 neutralization titers were higher in end-pandemic donors and correlated with OC43 S1 and S2-specific IgG titers and reactive B-cells frequencies.,10.1101/2025.09.28.25336743,1.0
OC43,OC43,correlate,Serum OC43 neutralization titers were higher in end-pandemic donors and correlated with OC43 S1 and S2-specific IgG titers and reactive B-cells frequencies.,10.1101/2025.09.28.25336743,1.0
OC43,OC43,correlate,Serum OC43 neutralization titers were higher in end-pandemic donors and correlated with OC43 S1 and S2-specific IgG titers and reactive B-cells frequencies.,10.1101/2025.09.28.25336743,1.0
OC43,OC43,correlate,Serum OC43 neutralization titers were higher in end-pandemic donors and correlated with OC43 S1 and S2-specific IgG titers and reactive B-cells frequencies.,10.1101/2025.09.28.25336743,1.0
OC43,OC43,correlate,Serum OC43 neutralization titers were higher in end-pandemic donors and correlated with OC43 S1 and S2-specific IgG titers and reactive B-cells frequencies.,10.1101/2025.09.28.25336743,1.0
OC43,OC43,correlate,Serum OC43 neutralization titers were higher in end-pandemic donors and correlated with OC43 S1 and S2-specific IgG titers and reactive B-cells frequencies.,10.1101/2025.09.28.25336743,1.0
OC43,OC43,correlate,Serum OC43 neutralization titers were higher in end-pandemic donors and correlated with OC43 S1 and S2-specific IgG titers and reactive B-cells frequencies.,10.1101/2025.09.28.25336743,1.0
OC43,OC43,correlate,Serum OC43 neutralization titers were higher in end-pandemic donors and correlated with OC43 S1 and S2-specific IgG titers and reactive B-cells frequencies.,10.1101/2025.09.28.25336743,1.0
OC43,OC43,correlate,Serum OC43 neutralization titers were higher in end-pandemic donors and correlated with OC43 S1 and S2-specific IgG titers and reactive B-cells frequencies.,10.1101/2025.09.28.25336743,1.0
OC43,OC43,correlate,Serum OC43 neutralization titers were higher in end-pandemic donors and correlated with OC43 S1 and S2-specific IgG titers and reactive B-cells frequencies.,10.1101/2025.09.28.25336743,1.0
OC43,OC43,correlate,Serum OC43 neutralization titers were higher in end-pandemic donors and correlated with OC43 S1 and S2-specific IgG titers and reactive B-cells frequencies.,10.1101/2025.09.28.25336743,1.0
OC43,OC43,correlate,Serum OC43 neutralization titers were higher in end-pandemic donors and correlated with OC43 S1 and S2-specific IgG titers and reactive B-cells frequencies.,10.1101/2025.09.28.25336743,1.0
OC43,OC43,correlate,Serum OC43 neutralization titers were higher in end-pandemic donors and correlated with OC43 S1 and S2-specific IgG titers and reactive B-cells frequencies.,10.1101/2025.09.28.25336743,1.0
OC43,OC43,correlate,Serum OC43 neutralization titers were higher in end-pandemic donors and correlated with OC43 S1 and S2-specific IgG titers and reactive B-cells frequencies.,10.1101/2025.09.28.25336743,1.0
OC43,OC43,correlate,Serum OC43 neutralization titers were higher in end-pandemic donors and correlated with OC43 S1 and S2-specific IgG titers and reactive B-cells frequencies.,10.1101/2025.09.28.25336743,1.0
OC43,OC43,correlate,Serum OC43 neutralization titers were higher in end-pandemic donors and correlated with OC43 S1 and S2-specific IgG titers and reactive B-cells frequencies.,10.1101/2025.09.28.25336743,1.0
OC43,OC43,correlate,Serum OC43 neutralization titers were higher in end-pandemic donors and correlated with OC43 S1 and S2-specific IgG titers and reactive B-cells frequencies.,10.1101/2025.09.28.25336743,1.0
OC43,OC43,correlate,Serum OC43 neutralization titers were higher in end-pandemic donors and correlated with OC43 S1 and S2-specific IgG titers and reactive B-cells frequencies.,10.1101/2025.09.28.25336743,1.0
OC43,OC43,correlate,Serum OC43 neutralization titers were higher in end-pandemic donors and correlated with OC43 S1 and S2-specific IgG titers and reactive B-cells frequencies.,10.1101/2025.09.28.25336743,1.0
OC43,OC43,correlate,"However, the SARS-CoV-2/OC43 S2 cross-reactive IgG clones did not independently correlate with OC43 neutralization titers.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,correlate,"However, the SARS-CoV-2/OC43 S2 cross-reactive IgG clones did not independently correlate with OC43 neutralization titers.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,correlate,"However, the SARS-CoV-2/OC43 S2 cross-reactive IgG clones did not independently correlate with OC43 neutralization titers.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,correlate,"However, the SARS-CoV-2/OC43 S2 cross-reactive IgG clones did not independently correlate with OC43 neutralization titers.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,correlate,"However, the SARS-CoV-2/OC43 S2 cross-reactive IgG clones did not independently correlate with OC43 neutralization titers.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,correlate,"However, the SARS-CoV-2/OC43 S2 cross-reactive IgG clones did not independently correlate with OC43 neutralization titers.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,correlate,"However, the SARS-CoV-2/OC43 S2 cross-reactive IgG clones did not independently correlate with OC43 neutralization titers.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,correlate,"However, the SARS-CoV-2/OC43 S2 cross-reactive IgG clones did not independently correlate with OC43 neutralization titers.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,correlate,"However, the SARS-CoV-2/OC43 S2 cross-reactive IgG clones did not independently correlate with OC43 neutralization titers.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,correlate,"However, the SARS-CoV-2/OC43 S2 cross-reactive IgG clones did not independently correlate with OC43 neutralization titers.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,correlate,"However, the SARS-CoV-2/OC43 S2 cross-reactive IgG clones did not independently correlate with OC43 neutralization titers.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,correlate,"However, the SARS-CoV-2/OC43 S2 cross-reactive IgG clones did not independently correlate with OC43 neutralization titers.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,correlate,"However, the SARS-CoV-2/OC43 S2 cross-reactive IgG clones did not independently correlate with OC43 neutralization titers.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,correlate,"However, the SARS-CoV-2/OC43 S2 cross-reactive IgG clones did not independently correlate with OC43 neutralization titers.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,correlate,"However, the SARS-CoV-2/OC43 S2 cross-reactive IgG clones did not independently correlate with OC43 neutralization titers.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,correlate,"However, the SARS-CoV-2/OC43 S2 cross-reactive IgG clones did not independently correlate with OC43 neutralization titers.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,correlate,"However, the SARS-CoV-2/OC43 S2 cross-reactive IgG clones did not independently correlate with OC43 neutralization titers.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,correlate,"However, the SARS-CoV-2/OC43 S2 cross-reactive IgG clones did not independently correlate with OC43 neutralization titers.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,correlate,"However, the SARS-CoV-2/OC43 S2 cross-reactive IgG clones did not independently correlate with OC43 neutralization titers.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,correlate,"However, the SARS-CoV-2/OC43 S2 cross-reactive IgG clones did not independently correlate with OC43 neutralization titers.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,correlate,"However, the SARS-CoV-2/OC43 S2 cross-reactive IgG clones did not independently correlate with OC43 neutralization titers.",10.1101/2025.09.28.25336743,1.0
sHCoVs,OC43,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,0.125
OC43,OC43,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,1.0
OC43,NL63,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,0.3333333333333333
OC43,OC43,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,1.0
OC43,NL63,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,0.3333333333333333
sHCoVs,OC43,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,0.125
sHCoVs,NL63,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,0.1
sHCoVs,OC43,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,0.125
sHCoVs,OC43,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,0.125
sHCoVs,OC43,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,0.125
sHCoVs,OC43,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,0.125
sHCoVs,OC43,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,0.125
sHCoVs,NL63,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,0.1
OC43,NL63,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,0.3333333333333333
OC43,OC43,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,1.0
OC43,NL63,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,0.3333333333333333
OC43,NL63,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,0.3333333333333333
OC43,NL63,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,0.3333333333333333
OC43,NL63,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,0.3333333333333333
OC43,NL63,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,0.3333333333333333
OC43,NL63,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,0.3333333333333333
NL63,NL63,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,1.0
OC43,NL63,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,0.3333333333333333
OC43,OC43,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,1.0
OC43,NL63,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,0.3333333333333333
OC43,OC43,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,1.0
OC43,OC43,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,1.0
OC43,NL63,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,0.3333333333333333
OC43,OC43,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,1.0
OC43,NL63,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,0.3333333333333333
OC43,NL63,conclude,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743,0.3333333333333333
SARS-CoV-2 infection,infection,analyze,"This study analyzes the composition of the oral microbiota in relation to age, household cohabitation, SARS-CoV-2 infection, and COVID-19 severity among children and adults under home confinement in Barcelona, Spain.",10.1101/2025.09.30.679491,0.5
SARS-CoV-2 infection,SARS-CoV-2 infection,analyze,"This study analyzes the composition of the oral microbiota in relation to age, household cohabitation, SARS-CoV-2 infection, and COVID-19 severity among children and adults under home confinement in Barcelona, Spain.",10.1101/2025.09.30.679491,1.0
SARS-CoV-2 infection,infection,analyze,"This study analyzes the composition of the oral microbiota in relation to age, household cohabitation, SARS-CoV-2 infection, and COVID-19 severity among children and adults under home confinement in Barcelona, Spain.",10.1101/2025.09.30.679491,0.5
SARS-CoV-2 infection,infection,analyze,"This study analyzes the composition of the oral microbiota in relation to age, household cohabitation, SARS-CoV-2 infection, and COVID-19 severity among children and adults under home confinement in Barcelona, Spain.",10.1101/2025.09.30.679491,0.5
infection,infection,analyze,"This study analyzes the composition of the oral microbiota in relation to age, household cohabitation, SARS-CoV-2 infection, and COVID-19 severity among children and adults under home confinement in Barcelona, Spain.",10.1101/2025.09.30.679491,1.0
SARS-CoV-2 infection,infection,analyze,"This study analyzes the composition of the oral microbiota in relation to age, household cohabitation, SARS-CoV-2 infection, and COVID-19 severity among children and adults under home confinement in Barcelona, Spain.",10.1101/2025.09.30.679491,0.5
SARS-CoV-2 infection,infection,confirm,"All 142 adults had a prior confirmed SARS-CoV-2 infection, and 20 (14.08%) of them had a history of severe COVID-19.",10.1101/2025.09.30.679491,0.5
SARS-CoV-2 infection,SARS-CoV-2 infection,confirm,"All 142 adults had a prior confirmed SARS-CoV-2 infection, and 20 (14.08%) of them had a history of severe COVID-19.",10.1101/2025.09.30.679491,1.0
SARS-CoV-2 infection,infection,confirm,"All 142 adults had a prior confirmed SARS-CoV-2 infection, and 20 (14.08%) of them had a history of severe COVID-19.",10.1101/2025.09.30.679491,0.5
SARS-CoV-2 infection,infection,confirm,"All 142 adults had a prior confirmed SARS-CoV-2 infection, and 20 (14.08%) of them had a history of severe COVID-19.",10.1101/2025.09.30.679491,0.5
infection,infection,confirm,"All 142 adults had a prior confirmed SARS-CoV-2 infection, and 20 (14.08%) of them had a history of severe COVID-19.",10.1101/2025.09.30.679491,1.0
SARS-CoV-2 infection,infection,confirm,"All 142 adults had a prior confirmed SARS-CoV-2 infection, and 20 (14.08%) of them had a history of severe COVID-19.",10.1101/2025.09.30.679491,0.5
infection,infection,detect,SARS-CoV2 infection was detected in 58/265 (21.89%) of children; all of them were asymptomatic.,10.1101/2025.09.30.679491,1.0
SARS-CoV-2 infection,infection,differ,Oral microbiota composition and diversity did not differ by SARS-CoV-2 infection status in children.,10.1101/2025.09.30.679491,0.5
SARS-CoV-2 infection,SARS-CoV-2 infection,differ,Oral microbiota composition and diversity did not differ by SARS-CoV-2 infection status in children.,10.1101/2025.09.30.679491,1.0
SARS-CoV-2 infection,infection,differ,Oral microbiota composition and diversity did not differ by SARS-CoV-2 infection status in children.,10.1101/2025.09.30.679491,0.5
SARS-CoV-2 infection,infection,differ,Oral microbiota composition and diversity did not differ by SARS-CoV-2 infection status in children.,10.1101/2025.09.30.679491,0.5
infection,infection,differ,Oral microbiota composition and diversity did not differ by SARS-CoV-2 infection status in children.,10.1101/2025.09.30.679491,1.0
SARS-CoV-2 infection,infection,differ,Oral microbiota composition and diversity did not differ by SARS-CoV-2 infection status in children.,10.1101/2025.09.30.679491,0.5
infection,infection,vary,"Our study demonstrates that oral microbiota composition in adults varies according to COVID-19 severity, whereas such microbial shifts are not observed in asymptomatic pediatric populations, regardless of infection status.",10.1101/2025.09.30.679491,1.0
K,DTLVardef@1696837_HPS_FORMAT_FIGEXP M_FIG,play,"Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=138 SRC=""FIGDIR/small/677528v1_ufig1.gif"" ALT=""Figure 1""> View larger version (27K): org.highwire.dtl.DTLVardef@131df69org.highwire.dtl.DTLVardef@1429b6corg.highwire.dtl.DTLVardef@1ea0eacorg.highwire.dtl.DTLVardef@1696837_HPS_FORMAT_FIGEXP M_FIG C_FIG AbstractRNA-Binding proteins (RBPs) play critical roles in host-virus interaction.",10.1101/2025.09.22.677528,0.09090909090909091
U/A,G/C,impact,"The majority of the RBPs with AU-rich binding motifs are reduced in the variants, while RBPs with mostly GC-rich motifs accumulate more binding positions, suggesting that a single change from U/A to G/C and vice versa can impact RBP- viral interactions.",10.1101/2025.09.22.677528,0.3333333333333333
